

TEXTBOOKS OF PSYCHOPHARMACOLOGY

- (TB-1) Stahl SM. Essential Psychopharmacology. Cambridge University Press, New York, 1996.
- (TB-2) Stahl SM. Psychopharmacology of Antidepressants. Martin Dunitz Press, London and Mosby, New York, 1997.
- (TB-3) Stahl SM. Psychopharmacology of Antipsychotics. Martin Dunitz Press, London, 1999.
- (TB-4) Stahl SM. Essential Psychopharmacology, 2nd Edition, Cambridge University Press, New York, 2000.
- (TB-5) Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder, Cambridge University Press, New York, New York, 2000.
- (TB-6) Stahl SM. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers, Cambridge University Press, New York, New York, 2002.
- (TB-7) Stahl SM. Essential Psychopharmacology: The Prescribers Guide. Cambridge University Press, New York, New York, 2005.
- TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)
- (TB-8) Stahl SM. Illustrated Insights – Sleep: Excessive Sleepiness. NEI Press, Carlsbad, CA 2005.
- (TB-9) Stahl SM. Essential Psychopharmacology: The Prescribers Guide Revised. 2nd edition, Cambridge University Press, New York, New York, 2006.
- (TB-10) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antipsychotics and Mood Stabilizers. Cambridge University Press, New York, New York, 2006.
- (TB-11) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antidepressants. Cambridge University Press, New York, New York, 2006.
- (TB-12) Stahl SM. Stahl's Essential Psychopharmacology, 3rd Edition. Cambridge University Press, New York, 2008.
- (TB-13) Stahl SM. Stahl's Essential Psychopharmacology of Depression and Bipolar Disorder. Cambridge University Press, New York, 2008.
- (TB-14) Stahl SM. Stahl's Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. Cambridge University Press, New York, 2008.
- (TB-15) Stahl SM. Stahl's Illustrated: Antipsychotics, Cambridge University Press, New York, New York 2009.

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

- (TB-16) Stahl SM. Essential Psychopharmacology: The Prescribers Guide 3rd Edition Cambridge University Press, New York, New York, 2009.
- (TB-17) Stahl SM. Stahl's Illustrated: Antidepressants. Cambridge University Press, New York, New York 2009.
- (TB-18) Stahl SM. Stahl's Illustrated: Mood Stabilizers. Cambridge University Press, New York, New York 2009.
- (TB-19) Stahl SM. Stahl's Illustrated: Chronic Pain and Fibromyalgia. Cambridge University Press, New York, New York 2009.
- (TB-20) Stahl SM. Stahl's Illustrated: Attention Deficit Hyperactivity Disorder. Cambridge University Press, New York, New York 2009.
- (TB-21) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antidepressants, 2nd Edition. Cambridge University Press, New York, New York, 2009.
- (TB-22) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antipsychotics and Mood Stabilizers, 2nd Edition. Cambridge University Press, New York, New York, 2009.
- (TB-23) Stahl SM and Davis RL. Best Practices for Medical Educators. NEI Press, 2009.
- (TB-24) Stahl SM. Stahl's Illustrated: Antipsychotics, 2nd Edition, Cambridge University Press, New York, New York, 2010.
- (TB-25) Stahl SM. Stahl's Illustrated: Anxiety and PTSD, Cambridge University Press, New York, 2010.
- (TB-26) Stahl SM. Essential Psychopharmacology Prescribers Guide 4th Edition, Cambridge University Press, London, 2011.
- (TB-27) Stahl SM. Essential Psychopharmacology Case Studies. Cambridge University Press, London, 2011.
- (TB-28) Stahl SM and Davis RL. Best Practices for Medical Educators, 2nd Edition. Cambridge University Press, 2011
- (TB-29) Stahl SM. Stahl's Self Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians. Cambridge University Press, 2012.
- (TB-30) Stahl SM and Grady M. Stahl's Illustrated: Drug Abuse and Disorders of Impulsivity. Cambridge University Press, New York, 2012.

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

- (TB-31) Stahl SM. Stahls Essential Psychopharmacology, 4th Edition. Cambridge University Press, New York, 2013.
- (TB-32) Stahl SM. Stahls Essential Psychopharmacology: the Prescribers Guide, 5th Edition. Cambridge University, New York, 2014.
- (TB-33) Stahl SM and Morrissette DA,. Stahl's Illustrated: Violence: Neural Circuits, Genetics and Treatment, Cambridge University Press, New York, 2014.
- (TB-34) Stahl SM, The Stahl Neuropsychopharmacology Masterclass: Mood Disorders, Cambridge University Press, Cambridge, UK, 2015.
- (TB-35) Stahl SM, The Stahl Neuropsychopharmacology Masterclass: Antidepressants, Cambridge University Press, Cambridge, UK, 2015
- (TB-36) Stahl SM. And Schwartz T, Essential Psychopharmacology Case Studies. Cambridge University Press, Volume 2, Cambridge, 2016.
- (TB-37) Stahl SM. Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians. 2nd edition, Cambridge University Press, 2016.
- (TB-38) Stahl SM and Morrissette DA. Stahls Illustrated: Sleep and Wake Disorders, Cambridge University Press, New York, 2016
- (TB-39) Stahl SM. Stahl's Essential Psychopharmacology: The Prescribers Guide, 6th Edition. Cambridge University, New York, 2017.
- (TB-40) Stahl SM. Stahl's Essential Psychopharmacology: The Prescribers Guide – Children and Adolescents, Cambridge University Press, 2018
- (TB-41) Stahl SM, Morrissette DA, Stahl's Illustrated Dementia, Cambridge University Press, 2018
- (TB-42) Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide to Antipsychotics, Cambridge University Press, 2018
- (TB-43) Stahl SM. Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians, 3rd Edition, Cambridge University Press, 2019
- (TB-44) Meyer, JM, Stahl SM. Stahl's Handbooks – The Clozapine Handbook, Cambridge University Press, 2020
- (TB-45) Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 7th edition, Cambridge University Press, New York, 2021

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

- (TB-46) Goldberg JF and Stahl SM. Practical Psychopharmacology: Translating Findings from Evidence-Based Trials into Real-World Clinical Practice, Cambridge University Press, New York, 2021
- (TB-47) Moutier C, Pisani A and Stahl SM. Stahl's Handbooks: Suicide Prevention., Cambridge University Press, New York, 2021
- (TB-48) Stahl SM. Stahl's Essential Psychopharmacology 5th edition, Cambridge University Press, New York, 2021
- (TB-49) Cummings MA and Stahl SM. Management of Complex Treatment-resistant Psychotic Disorders, Cambridge University Press, New York, 2021
- (TB-50) Meyer JM and Stahl SM. Stahl's Handbooks: The Clinical Use of Antipsychotic Plasma Levels, Cambridge University Press, New York, 2021
- (TB-51) Cooper T, Maguire G and Stahl SM. Case Studies: Stahl's Essential Psychopharmacology, Volume 3, Cambridge University Press, New York, 2022
- (TB-52) Stahl SM. Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians, 4th Edition, Cambridge University Press, New York, 2022
- (TB-53) Stahl SM and Segal, S. Stahl's Illustrated Treatments for Mood Disorders, 2nd Edition, Cambridge University Press, New York for 2023
- (TB-54) Meyer JM and Stahl SM. Stahl's Handbooks: The Lithium Handbook, Cambridge University Press, New York for 2023
- (TB-55) Hafizi S, Jones PB and Stahl SM. Cambridge Prescribing Guidelines for Psychiatrists, Cambridge University Press, New York, 2024
- (TB-56) Lynell ML, Jones PB and Stahl SM. Cambridge Textbook of Neuroscience for Psychiatrists, Cambridge University Press, New York, 2024
- (TB-57) Strawn JR and Stahl SM. Case Studies: Stahl's Essential Psychopharmacology, Volume 5, Cambridge University Press, New York, 2024
- (TB-58) Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 8th edition, Cambridge University Press, New York, 2024
- (TB-59) Goldberg JF and Stahl SM. Clinical Reasoning and Decision-Making in Psychiatry, Cambridge University Press, New York, 2024

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

- (TB-60) Schwartz T and Stahl SM. Case Studies: Stahl's Essential Psychopharmacology, Volume 4, Cambridge University Press, New York, 2024
- (TB-61) Stahl SM and Alarcon G, Stahl's Illustrated Pharmacological Treatments for Psychosis, 2nd edition, Cambridge University Press, New York, 2024
- (TB-62) Stahl SM. and Strawn JR Stahl's Essential Psychopharmacology: The Prescribers Guide – Children and Adolescents, Cambridge University Press, 2nd edition, 2024

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

(in press)

- (TB-63) Klein, C and Stahl SM. Forensic Case Studies: Stahl's Essential Psychopharmacology, Volume 6, Cambridge University Press, New York for 2024

TEXTBOOKS OF PSYCHOPHARMACOLOGY

(in preparation)

- (TB-64) Finley P, Saklad S and Stahl SM. Stahl's Handbooks: Drug Interactions with Psychiatric Medications, Cambridge University Press, New York for 2024
- (TB-65) Goldberg JF and Stahl SM. How to Manage Difficult-to-Treat Psychiatric Conditions, Cambridge University Press, New York, 2024
- (TB-66) Stahl SM. And McIntyre R, Stahl's Essential Psychopharmacology 6th edition, Cambridge University Press, New York, for 2025
- (TB-67) Stahl SM. Stahl's Select a Symptom and Guide to Treatment Resistance and Side Effects in Psychiatry: Deconstructing the DSM for Rational Prescribing: Symptoms and Circuits, Cambridge University Press for 2025
- (TB-68) Stahl SM. Neuroscience, Drugs and Behavior: Essential Psychopharmacology Student adaptation, Cambridge University Press, New York for 2025

EDITED BOOKS

- (EB-1) Stahl SM, Iversen SD and Goodman EC (Eds). Cognitive Neurochemistry: Assessment Techniques and Research Strategies for Understanding the Pharmacologic Basis of Human Neuropsychology. Oxford University Press, Oxford, 1987.
- (EB-2) Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J (Eds). Serotonin 1A Receptors in Depression and Anxiety. Raven Press, New York, 1992.
- (EB-3) Stein DJ, Lerer B and Stahl SM. (Eds). Evidence Based Psychopharmacology. Cambridge University Press, New York, 2005.
- (EB-4) Beyer CE and Stahl SM. (Eds.) Next Generation Antidepressants, Cambridge University Press, Cambridge, UK, 2010.
- (EB-5) Silberstein SD, Marmura MJ and Stahl SM (Ed). Essential Neuropharmacology, The Prescribers Guide, Cambridge University Press, Cambridge UK, 2010.
- (EB-6) Kalali A, Kwentus J, Preskorn S, Stahl SM (Eds), Essential CNS Drug Development, Cambridge University Press, New York, 2012
- (EB-7) Stein DJ, Lerer B, Stahl SM (Eds), Essential Evidence Based Psychopharmacology, 2nd Edition, Cambridge University Press, New York, 2012
- (EB-8) Pappagallo M, Smith H and Stahl SM. Essential Pain Pharmacology: Prescribers Guide. Cambridge University Press, New York, 2012.
- (EB-9) Stahl SM and Moore BA. (Eds) Anxiety Disorders: A Concise Guide and Casebook for Psychopharmacology and Psychotherapy Integration. Routledge Press, New York, 2013.
- (EB-10) Reis de Oliveira I , SchwartzT and Stahl SM. Integrating Psychotherapy and Psychopharmacology. Routledge Press, New York 2014.
- (EB-11) Zohar J, Stahl S, Moller H-J, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin G, Nutt D. Neuroscience Based Nomenclature, Cambridge University Press, Cambridge, UK, 2014
- (EB-12) Silberstein, SD, Marmura MJ, Hsiangkuo Y, Stahl SM. Essential Neuropharmacology, The Prescribers Guide, 2nd Edition, 2016, Cambridge University Press, New York.
- (EB-13) Warburton KD and Stahl SM. Violence in Psychiatry, Cambridge University Press, 2016
- (EB-14) Marazzitti D and Stahl SM. Evil, Terrorism and Psychiatry, Cambridge University Press, 2019

EDITED BOOKS (Cont.)

- (EB-15) Warburton KD and Stahl SM. Decriminalizing Mental Illness, Cambridge University Press, New York, 2021

EDITED BOOKS (Cont.) (in preparation)

- (EB-16) Warburton KD and Stahl SM. Ethical and Clinical Complexities in the Treatment of Schizophrenia: Liberty Over Life, Cambridge University Press, New York, for 2025
- (EB-17) Dodd S, Stahl SM, and Berk, M., Recreational Drugs Repurposed for Medicinal Use, Cambridge University Press, New York, for 2025

OTHER BOOKS – NOVELS (fiction/thrillers)

- (Novel-1) Stahl SM. Shell Shock, the story of PTSD, Harley House Press, San Diego, 2015
- (Novel-2) Stahl SM. The T4 Project, the story of psychiatric euthanasia, Harley House Press, San Diego, in preparation

OTHER BOOKS – NONFICTION/TRADE

- (Trade-1) Perko M and Stahl SM. Tesla: His tremendous and troubled life, the story of Tesla's genius and bipolar disorder, Prometheus Books/Rowman and Littlefield, New York, 2022

PUBLICATIONS

1. 1971 Stahl SM, Zeller EA and Boshes B. On the effect of modulation of cerebral amine metabolism on the learning and memory of goldfish (*Carassius auratus*). Transactions of the American Neurological Association 96:310-312, 1971.
2. 1971 Stahl SM, Narotzky R, Boshes B and Zeller EA. Einfluß des zerebralen Amin-Stoffwechsels auf das Gedächtnis des Goldfisches. (Influences of Cerebral amine metabolism on the memory of goldfish). Die Naturwissenschaften 58:628-629, 1971.
3. 1973 Boshes B, Zeller EA, Arbit J, Blonsky ER, Dolkart M and Stahl SM. Influence of L-DOPA on selected aspects of learning and performance. In: Psycho-Physiological Approach of Behavior. Department of Neurology and Biochemistry, Northwestern University-McGrawn Medical Center, Chicago, IL
4. 1973 Narotzky R, Griffit D, Stahl SM, Bondareff W and Zeller EA. Effect of Long-Term L-DOPA Administration of Brain Biogenic Amines and Behavior in the Rat. Experimental Neurology, Volume 38, No. 2, 218-230.
5. 1974 Meltzer HY and Stahl SM. Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. Research Communications in Chemical Pathology and Pharmacology 7:419-431, 1974.
6. 1974 Spehlmann R and Stahl SM. Neuronal hyposensitivity to dopamine in the caudate nucleus depleted of biogenic amines by tegmental lesions. Experimental Neurology 42(3):703-706, 1974.
7. 1974 Stahl SM, Narotzky RA, Boshes B and Zeller EA. The effects of cerebral amine metabolism on operationally defined learning and memory processes of goldfish. Biological Psychiatry 9(3):295-323, 1974. (A.E. Bennett Basic Research Award paper).
8. 1975 Stahl SM, Daniels AC, Derda D and Spehlmann R. Injection of 6-hydroxydopamine and hydrogen peroxide into the substantia nigra and lateral ventricle of the cat: specific and non-specific effects on striatal biogenic amines. Journal of Neurochemistry 24:165-172, 1975.
9. 1975 Schmidt RT, Stahl SM and Spehlmann R. A pharmacologic study of the stiff-man syndrome: correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol excretion. Neurology 25(7):622-626, 1975.
10. 1975 Drachman DA and Stahl SM. Extrapyrimalid dementia and levodopa. Lancet I: 809, 1975.
11. 1976 Meltzer HY and Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bulletin 2(1):19-76, 1976.

PUBLICATIONS (2)

12. 1976 Spehlmann R and Stahl SM. Dopamine-acetylcholine imbalance in Parkinson's disease: possible regenerative overgrowth of cholinergic axon terminals. Lancet I:724-726, 1976.
13. 1976 Stahl SM. The human platelet as a model for the central nervous system amine-containing neuron. Ph.D. dissertation, Department of Pharmacological and Physiological Sciences Neuropharmacology, University of Chicago, 1976.
14. 1977 Stahl SM and Meltzer HY. Serotonin accumulation by skeletal muscle. Experimental Neurology 54:42-53, 1977.
15. 1977 Stahl SM. The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Archives of General Psychiatry 34:509-516, 1977.
16. 1977 Hanley HG, Stahl SM and Freedman DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Archives of General Psychiatry 34:521-531, 1977.
17. 1978 Stahl SM and Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. Journal of Pharmacology and Experimental Therapeutics 205(1):118-132, 1978.
18. 1978 Stahl SM and Meltzer HY. The human platelet as a model for the dopaminergic neuron: kinetic and pharmacologic properties and the role of amine storage granules. Experimental Neurology 59:1-15, 1978.
19. 1979 Stahl SM, Ellinger G and Baringer JR. Progressive myelopathy due extramedullary hematopoiesis: case report and review of the literature. Annals of Neurology (5):485-489, 1979.
20. 1980 Stahl SM, Johnson KP and Malamud N. The clinical and pathological spectrum of brain-stem vascular malformations: long-term course simulates multiple sclerosis. Archives of Neurology 37:25-29, 1980.
21. 1980 Stahl SM, Layzer RB, Aminoff MJ, Townsend JJ and Feldon SF. Continuous cataplexy in a patient with a midbrain tumor: the limp-man syndrome. Neurology 30:1115-1118, 1980.
22. 1980 Stahl SM and Berger PA. Physostigmine in Gilles de la Tourette's syndrome. New England Journal of Medicine 302:298, 1980.
23. 1980 Stahl SM and Berger PA. Cholinergic treatment in the Tourette syndrome. New England Journal of Medicine 302(23):1310-1311, 1980.

PUBLICATIONS (3)

24. 1980 Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. American Journal of Psychiatry 137(10):1267-1269, 1980.
25. 1980 Davis KL, Hollister LE, Stahl SM and Berger PA. Choline chloride in Huntington's disease. Transactions of the American Neurological Association 105:464-467, 1980.
26. 1981 Stahl SM and Berger PA. Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. American Journal of Psychiatry 138 (2): 240-242, 1981.
27. 1981 Zelazowski R, Golden CJ, Graber B, Blose IL, Bloch S, Moses JA, Zatz LM, Stahl SM, Osmon DC and Pfefferbaum A. Relationship of cerebral ventricular size to alcoholics' performance on the Luria- Nebraska Neuropsychological Battery. Journal of Studies on Alcohol 42(9):749-756, 1981.
28. 1981 Stahl SM and Berger PA. Bromocriptine in dystonia. Lancet II:745, 1981.
29. 1982 Stahl SM, Levin B and Freedman DX. Serotonin depletion by Fenfluramine in the carcinoid syndrome. New England Journal of Medicine 306(7):429, 1982.
30. 1982 Stahl SM and Berger PA. Cholinergic and dopaminergic mechanisms in Tourette syndrome. In: Chase TN and Friedhoff AJ (Eds), Gilles de la Tourette Syndrome. Advances in Neurology, Volume 35, Chapter 18, Raven Press, New York, pp. 141-150, 1982.
31. 1982 Stahl SM and Berger PA. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 32:889-892, 1982.
32. 1982 Stahl SM, Ciaranello RD and Berger PA. Platelet serotonin in schizophrenia and depression. In: Ho BT, Schoolar JC and Usdin E (Eds), Serotonin in Biological Psychiatry, Advances in Biochemical Psychopharmacology, Volume 34, Raven Press, New York, 1982, pp.183-198.
33. 1982 Stahl SM and Berger PA. Neuroleptic effects in Tourette syndrome predict dopamine excess and acetylcholine deficiency. Biological Psychiatry 17(9):1047-1053, 1982.
34. 1982 Stahl SM, Davis KL and Berger PA. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia and other dystonias. Journal of Clinical Psychopharmacology 2(5):321-328, 1982.

PUBLICATIONS (4)

35. 1982 Stahl SM, Yesavage JA and Berger PA. Pharmacologic characteristics of Meige dystonia: differentiation from tardive dyskinesia. Journal of Clinical Psychiatry 43(11):445-446, 1982.
36. 1983 Stahl SM, Woo DJ, Mefford IN, Berger PA and Ciaranello RD. Hperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. American Journal of Psychiatry 140:26-30, 1983.
37. 1983 Stahl SM and Kasser IS. Pentazocine overdose. Annals of Emergency Medicine 12(1):28-31, 1983.
38. 1983 Stahl SM, Lemoine PM, Ciaranello RD and Berger PA. Platelet alpha-2 adrenergic receptor sensitivity in major depressive disorder. Psychiatry Research 10:157-164, 1983.
39. 1984 Stahl SM and Kasser IS. High-dose naloxone for pentazocine overdose (correspondence). Annals of Emergency Medicine 13(1):66,1984.
40. 1984 Stahl SM, Berger PA, Newman RP and Lewitt P. Bromocriptine and lisuride in dystonias (correspondence). Neurology 34:135-136, 1984.
41. 1984 Thornton JE and Stahl SM. Case report of tardive dyskinesia and Parkinsonism associated with amoxapine therapy. American Journal of Psychiatry 141(5):704-705, 1984.
42. 1984 Stahl SM and Tinklenberg JR. Dietary enhancement of CNS neurotransmitters (commentary). Integrative Psychiatry 2:157-159,1984.
43. 1984 Uhr S, Stahl SM and Berger PA. Unmasking schizophrenia. VA Practitioner 1:42-47, 1984.
44. 1984 Uhr S, Berger PA, Pruitt B and Stahl SM. Treatment of Tourette's syndrome with RO22-1319, a D-2 receptor antagonist. New England Journal of Medicine 311(15):989, 1984.
45. 1984 Stahl SM. Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action. Journal of Clinical Psychiatry 45(10)(sec.2):37-44, 1984.
46. 1985 Stahl SM. Serotonin agonists and beta-adrenergic agonists as a treatment for depressive disorder: a direct clinical application. Psychopharmacology Bulletin 21(1):43-47, 1985.

PUBLICATIONS (5)

47. 1985 Stahl SM. Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons. In: Longenecker G (Ed), The Platelets: Physiology and Pharmacology, Academic Press, New York 1985, Chapter 13, pp 307-340.
48. 1985 Stahl SM. Akathisia and tardive dyskinesia: changing concepts. Archives of General Psychiatry 42:915-917, 1985. Stahl SM. Akathisia variants and tardive dyskinesia. Letter to the Editor in Archives of General Psychiatry 43:1015, 1986.
49. 1985 Stahl SM. Can CSF measures distinguish among schizophrenia, depression, movement disorders, and dementia? Psychopharmacology Bulletin 21(3):396-399, 1985.
50. 1985 Stahl SM. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacology Bulletin 21(3):663-671, 1985.
51. 1985 Stahl SM, Thornton JE, Simpson ML, Berger PA and Napoliello MJ. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biological Psychiatry 20:888-893, 1985.
52. 1985 Stahl SM. Approches nouvelles de la biologie de la depression (New approaches to the biology of depression). Psychiatrie Francophone 1:6-21, 1985.
53. 1985 Stahl SM, Uhr SB and Berger PA. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. Biological Psychiatry 20:1098-1102, 1985.
54. 1985 Stahl SM, Thornton JE and Berger PA. Gamma-amino-butyric acid (GABA) and movement disorders: role of gamma-vinyl-GABA. In: Burrows G, Norman T and Dennerstein (Eds), Clinical and Pharmacological Studies in Psychiatric Disorders, John Libbey, London, 1985, pp. 216-221. (Vol.5 of Biological Psychiatry – New Prospects).
55. 1985 Jernigan TL, Sargent T, Pfefferbaum A, Kusubov N and Stahl SM. ¹⁸Fluorodeoxyglucose PET in Schizophrenia. Psychiatry Research 16:317-329, 1985.
56. 1985 King R, Faull K, Stahl S, Mefford I, Thiemann S, Barchas J and Berger P. Serotonin and schizophrenia: correlations between serotonergic activity and schizophrenic motor behavior. Psychiatry Research 4(3):235-240, 1985.
57. 1986 Grandas-Perez F, Jenner PG, Nomoto M, Stahl S, Quinn NP, Parkes JD, Critchley P and Marsden CD. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson's disease. Lancet April 19, 1986, 906.

PUBLICATIONS (6)

58. 1986 Uhr SB, Pruitt B, Berger PA and Stahl SM. Case report of four patients with Tourette syndrome treated with piquindone, a D₂ receptor antagonist. Journal of Clinical Psychopharmacology 6(2):128-130, 1986.
59. 1986 Stahl SM. Neuropharmacology of movement disorders: comparison of spontaneous and drug-induced movement disorders. In: Shah NS and Donald AG (Eds), Movement Disorders, Plenum Publishing Co., New York, 1986, pp. 1-36.
60. 1986 Stahl SM, Leenders KL and Bowery NG. Imaging neurotransmitters and their receptors in living human brain by positron emission tomography. Trends in Neurosciences 9(6):241-245, 1986.
61. 1986 Uhr SB, Pruitt B, Berger PA and Stahl SM. Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist. International Clinical Psychopharmacology 1:216-220, 1986.
62. 1986 Stahl SM and Palazidou L. The pharmacology of depression: studies of neurotransmitter receptors lead the search for biochemical lesions and new drug therapies. Trends in Pharmacological Sciences 7(9):349-354, 1986.
63. 1986 Stahl SM. Tardive dyskinesia: natural history studies assist the pursuit of preventive therapies. Psychological Medicine 16:491-494, 1986.
64. 1986 Stahl SM and Kravitz KD. A critical review of the use of laboratory tests in psychiatric disorders. In: Berger PA and Brodie HKH (Eds), American Handbook of Psychiatry, Volume VIII, Basic Books, Inc., New York, 1986, Chapter 35, pp. 1048-1084.
65. 1987 Williams JR, Spencer PS, Stahl SM, Borzelleca JF, Nichols W, Pfitzer E, Yunis EJ, Carchman R, Opishinski JW and Walford RA. Interactions of aging and environmental agents: the toxicological perspective. In: Baker SR and Rogul M (Eds), Environmental Toxicity and The Aging Processes, Progress in Clinical and Biological Research, Vol. 228, Alan R. Liss Inc., New York, 1987, pp. 81-135.
66. 1987 Nomoto M, Stahl SM, Jenner P and Marsden CD. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Movement Disorders 2(1):37-45, 1987.
67. 1987 Grandas F, Quinn N, Critchley P, Rohan A, Marsden CD and Stahl SM. Antiparkinsonian activity of a single oral dose of PHNO. Movement Disorders 2(1):47-51, 1987.

PUBLICATIONS (7)

68. 1987 Stahl SM. Needs and opportunities for innovation in psychopharmacology. Journal of the Royal Society of Medicine 80(7):413-417, 1987.
69. 1987 Stahl SM and Wets K. Indoleamines and schizophrenia. In: Henn FA and DeLisi LE (Eds), Handbook of Schizophrenia, Vol. 2: Neurochemistry and Neuropharmacology of Schizophrenia, Elsevier Science Publishers B.V., 1987, pp. 257-296.
70. 1987 Cohen JD, Van Putten T, Marder S, Berger PA and Stahl SM. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology 7(5):324-329, 1987.
71. 1987 Beer M, Hacker S, Poat J and Stahl SM. Independent regulation of β_1 - and β_2 -adrenoceptors. British Journal of Pharmacology 92:827- 834, 1987.
72. 1987 Martin-Iverson MT, Stahl SM and Iversen SD. Factors determining the behavioural consequences of continuous treatment with 4-propyl-9-hydroxynaphthoxazine, a selective dopamine D2 agonist. In: Rose FC (Ed), Parkinson's Disease: Clinical and Experimental Advances, John Libbey, London, 1987, pp. 169-177.
73. 1987 Coleman RJ, Grandas-Perez F, Quinn N, Jenner P, Nomoto M, Marsden CD and Stahl SM. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson's disease and MPTP models. In: Rose FC (Ed), Parkinson's Disease: Clinical and Experimental Advances, John Libbey, London, 1987, pp. 179-187.
74. 1987 Stahl SM, Beer M, Hacker S, Poat J and Iversen LL. Beta₁- and Beta₂-adrenoceptor regulation in rat nervous system by chronic treatment with desipramine and beta-adrenoceptor agonists. Psychopharmacology Bulletin 23(3):473-475, 1987.
75. 1987 Cohen JD, Van Putten T, Marder SR and Stahl SM. Treatment of the symptoms of schizophrenia with piquindone: a new atypical neuroleptic. Psychopharmacology Bulletin 23(3):514-518, 1987.
76. 1987 Reiss AL and Stahl SM. Inpatient clinical research: its importance in psychiatry and psychopharmacology. In: Alarcon RD and Walter-Ryan WG (Eds), Psychiatric Medicine 4(4):407-416, 1987.
77. 1988 Stahl SM and Wets KM. Recent advances in drug delivery technology for neurology. Clinical Neuropharmacology 11(1):1-17, 1988.
78. 1988 Stahl SM, Jernigan T, Pfefferbaum A and Zatz L. Brain computerized tomography in subtypes of severe chronic schizophrenia. Psychological Medicine 18:73-77, 1988.

PUBLICATIONS (8)

79. 1988 Beer M, Richardson A, Poat J, Iversen LL and Stahl SM. In vitro selectivity of agonists and antagonists for Beta₁- and Beta₂-adrenoceptor subtypes in rat brain. Biochemical Pharmacology 37(6):1145-1151, 1988.
80. 1988 Reiss AL, Harris JC and Stahl SM. Inpatient psychiatric research. Psychiatric Annals 18(2):97-101, 1988.
81. 1988 Coleman RJ, Grandas-Perez F, Quinn N, Jenner P, Nomoto M, Marsden D and Stahl S. 4-propyl-9-hydroxynaphthoxazine in Parkinson's disease and MPTP models. In: Fahn S, Marsden CD, Calne DB and Goldstein M (Eds), Recent Developments in Parkinson's Disease, Vol. II, Macmillan Healthcare Information, New Jersey, 1988, pp. 269-278.
82. 1988 Gilbert F, Brazell C, Tricklebank M and Stahl SM. Activation of the 5HT_{1A} receptor subtype increases rat plasma ACTH concentration. European Journal of Pharmacology 147:431-439, 1988.
83. 1988 Stahl SM. Applications of new drug delivery technologies to Parkinson's disease and dopaminergic agents. Journal of Neural Transmission (Suppl) 27:123-132, 1988.
84. 1988 Martin-Iverson MT, Iversen SD and Stahl SM. Long-term motor stimulant effects of (+)-4-propyl-9-hydroxy-naphthoxazine (PHNO), a dopamine D-2 receptor agonist: interactions with a dopamine D-1 receptor antagonist and agonist. European Journal of Pharmacology 149:25-31, 1988.
85. 1988 Palazidou E, Beer M, Checkley S and Stahl SM. Pharmacologic exploitation of neurotransmitter receptors for the design of novel antidepressant drugs. Drug Design and Delivery 2:247-256, 1988.
86. 1988 Martin-Iverson MT, Stahl SM and Iversen SD. Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization. Psychopharmacology Berlin 95(4):534-539, 1988.
87. 1988 Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM and Jernigan TL. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Archives of General Psychiatry 45(7):633-640, 1988.
88. 1988 Stahl SM, Moratalla R and Bowery NG. Neurotransmitter receptor imaging in living human brain with positron emission tomography. Journal of Mind & Behavior 9:367-384, 1988.

PUBLICATIONS (9)

89. 1988 Stahl SM. The biochemistry of depression. Journal de psychiatrie biologique et therapeutique 30:44-53, 1988.
90. 1988 Stahl SM. Basal ganglia neuropharmacology and obsessive-compulsive disorder: the obsessive-compulsive disorder hypothesis of basal ganglia dysfunction. Psychopharmacology Bulletin 24:370-374, 1988.
91. 1988 Stahl SM. Treatment of the on-off dyskinesia syndrome of Parkinson's disease with new drug delivery technologies for selective dopamine-2 receptor agonists. In: Wolf ME and Mosnaim AD Eds), Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects, American Psychiatric Press, Washington, DC, 1988, pp. 233-242.
92. 1988 Broks P, Preston GC, Traub M, Poppleton P, Ward C and Stahl SM. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26(5):685-700, 1988.
93. 1988 Gilbert F, Dourish CT, Brazell C, McClue S and Stahl SM. Relationship of increased food intake and plasma ACTH levels to 5-HT_{1A} receptor activation in rats. Psychoneuroendocrinology 13(6):471-478, 1988.
94. 1988 Preston GC, Broks P, Traub M, Ward C, Poppleton P and Stahl SM. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology (Berlin) 95(2):208- 215, 1988.
95. 1988 Clarke CE, Boyce S, Sambrook MA, Stahl SM and Crossman AR. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn-Schmiedeberg's Archives of Pharmacology 338(1):35-38, 1988.
96. 1988 Schwartzman RJ, Alexander GM, Ferraro TN, Grothusen JR and Stahl SM. Cerebral metabolism of parkinsonian primates 21 days after MPTP. Experimental Neurology 102(3):307-313, 1988.
97. 1988 Stahl SM and Wets KM. Clinical pharmacology of schizophrenia. In: Bebbington P and McGuffin P (Eds), Schizophrenia: the Major Issues (based on the Mental Health Foundation Conference, New Initiatives in Schizophrenia Research), Heinemann Professional Publishing, Oxford, 1988, pp. 135-157.
98. 1988 Carpenter WT, Schooler NR, Wise SS, Goldman H, Goldstein MJ, Hogarty GE, Jeste D, Kane JM, Klerman GL, Liberman RP, Paul SM, Robinson DS, Spring B, Stahl SM and Tamminga CA. Treatment, Services and Environmental Factors Panel. A National Plan for Schizophrenia Research: Report of the National Advisory Mental Health Council. NIMH, 1988, pp. 34-38.

PUBLICATIONS (10)

99. 1988 Coleman RJ, Jenner P, Marsden CD and Stahl SM. Effects of (+)-4-propyl-9-hydroxynaphthoxazine, a new dopamine agonist, in Parkinson's disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. For: 6th International Catecholamine Symposium, Jerusalem, Israel, June 14, 1987, Alan R.Liss, Inc. In: Liss AR (Ed). Progress in Catecholamine Research Part C: Clinical Aspects, 1988, pp. 19-23.
100. 1988 Preston GC, Brazell C, Ward C, Broks P, Traub M and Stahl SM. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. Journal of Psychopharmacology 2(2):67-79, 1988.
101. 1989 Carpenter WT, Schooler NR, Wise SS, Goldman H, Goldstein MJ, Hogarty GE, Jeste D, Kane JM, Klerman GL, Liberman RP, Paul SM, Robinson DS, Spring B, Stahl SM and Tamminga CA. Treatment Services, and Environmental Factors. A National Plan for Schizophrenia Research: Panel Recommendations. Schizophrenia Bulletin 14(3):425-437, 1988; and NIMH, 1989, pp. 82-92.
102. 1989 Stahl SM. Agonist-induced down-regulation of α_1 adrenergic receptors: possible biochemical rationale for novel antidepressants. In: Lerer B and Gershon S (Eds), New Directions in Affective Disorders, Springer-Verlag, New York, 1989, pp. 25-38.
103. 1989 Palazidou E, Papadopoulos A, Sitsen A, Stahl S and Checkley S. An α_2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology 97:115-117, 1989.
104. 1989 Rupniak NMJ, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Iversen SD and Stahl SM. Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in Parkinsonian squirrel monkeys. Journal of Neurology, Neurosurgery and Psychiatry 52:289-290, 1989.
105. 1989 Rupniak NMJ, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Hand E, Iversen SD and Stahl SM. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 39(3):329-335, 1989.
106. 1989 Preston GC, Ward CE, Broks P, Traub M and Stahl SM. Effects of lorazepam on memory, attention and sedation in man: antagonism by Ro 15-1788. Psychopharmacology (Berlin) 97(2):222-227, 1989.
107. 1989 McClue SJ, Brazell C and Stahl SM. Hallucinogenic drugs are partial agonists of the human platelet shape change response: a physiological model of the 5-HT₂ receptor. Biological Psychiatry 26(3):297-302, 1989.

PUBLICATIONS (11)

108. 1989 Obeso JA and Stahl SM. New routes of administration for antiparkinsonian therapy. In: Calne DB (Ed), Drugs for the treatment of Parkinson's Disease, Handbook of Experimental Pharmacology, Springer-Verlag, Germany, 1989, pp. 531-541.
109. 1989 Coleman RJ, Temlett JA, Quinn NP, Stahl SM and Marsden CD. A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations. Clinical Neuropharmacology 12(1):37-45, 1989.
110. 1989 Palazidou E, Franey C, Arendt J, Stahl S and Checkley S. Evidence for a functional role of alpha₁ adrenoceptors in the regulation of melatonin secretion in man. Psychoneuroendocrinology 14(1-2):131-135, 1989.
111. 1989 Coleman RJ, Lange KW, Quinn NP, Loper AE, Bondi JV, Hichens M, Stahl SM and Marsden CD. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Movement Disorders 4(2):129-138, 1989.
112. 1989 Brazell C, Zentner GM, Gardner CR, Jenner P and Stahl SM. Delivery of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] by a novel orally administered osmotic tablet: behavioural effects in animal models of Parkinson's disease. In: Quinn NP and Jenner PG (Eds), Disorders of Movement, Academic Press, London, 1989, pp. 209-222.
113. 1989 Coleman RJ, Temlett JA, Nomoto M, Quinn NP, Jenner P and Stahl SM. The antiparkinsonian effects of transdermal +PHNO. In: Quinn NP and Jenner PG (Eds), Disorders of Movement, Academic Press, London, 1989, pp. 147-155.
114. 1990 Twist EC, Mitchell S, Brazell C, Stahl SM and Campbell IC. 5HT₂ receptor changes in rat cortex and platelets following chronic ritanserin and clorgyline administration. Biochemical Pharmacology 39(1):161-166, 1990.
115. 1990 Traub M and Stahl SM. Therapeutic potential of a novel dopamine agonist, naxagolide. In: Koller WC and Paulson G (Eds), Therapy of Parkinson's Disease, Marcel Dekker Inc., New York, 1990, pp. 325-332.
116. 1990 Rausch JL, Stahl SM and Hauger RL. Cortisol and growth hormone responses to the 5-HT_{1A} agonist gepirone in depressed patients. Biological Psychiatry 28:73-78, 1990.
117. 1990 Stahl SM, Rausch JL and Hauger RL. 5HT_{1A} neuroendocrine diagnostic and efficacy markers in depression. In: Stefanis CN, Rabavilas AD and Soldatos CR (Eds), Psychiatry: A World Perspective: Proceedings of the VIII World Congress of Psychiatry, Athens, 12-18 October 1989, Vol. 2, Excerpta Medica, Elsevier Science Publishers B.V., Amsterdam, 1990, pp. 331-333.

PUBLICATIONS (12)

118. 1990 Coleman RJ and Stahl SM. Movement disorders. In: Dinan TG (Ed), Principles and Practice of Biological Psychiatry, Clinical Neuroscience Publishers, London, 1990, pp. 183-203.
119. 1991 Stahl SM. Pipothiazine. In: Dollery C (Ed), Therapeutic Drugs, Churchill Livingstone, Edinburgh, 1991, pp. P120-P132.
120. 1991 Stahl SM. Trazodone (hydrochloride). In: Dollery C Ed), Therapeutic Drugs, Churchill Livingstone, Edinburgh, 1991, pp. T115-T119.
121. 1991 Stahl SM. Serotonin receptors and the mechanism of action of antidepressants drugs. In: Racagni G, et al, (Eds), Biological Psychiatry, Vol. 2. Elsevier Science Publishers B.V., Amsterdam, 1991, pp. 898-900.
122. 1991 Brazell C, McClue SJ, Preston GC, King B and Stahl SM. 5-hydroxytryptamine (5HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [¹²⁵I]-iodoLSD binding at 5HT₂ receptors. Blood Coagulation and Fibrinolysis 2:17-24, 1991.
123. 1992 Stahl SM. Serotonin receptors and the mechanism of action of antidepressant drugs: postmortem, platelet and neuroendocrine studies in depressed patients. In: Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J, (Eds), Serotonin 1A Receptors in Depression and Anxiety. Raven Press, New York, 1992, pp. 119-134.
124. 1992 Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J. New vistas for serotonin 1A agonists in psychiatry. In: Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J, (Eds), Serotonin 1A Receptors in Depression and Anxiety, Raven Press, New York, 1992, pp. 201-205.
125. 1992 Freedman DX and Stahl SM. Pharmacology: policy implications of new psychiatric drugs. Health Affairs 11(3):157-163, 1992.
126. 1992 Stahl SM. Neuroendocrine markers of serotonin responsivity in depression. Progress in NeuroPsychopharmacology and Biological Psychiatry 16:655-659,1992.
127. 1992 Stahl SM. Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry. Psychopharmacology Bulletin 28(1):3-9, 1992.
128. 1992 Freedman DX and Stahl SM. Contempo 1992: Psychiatry. Journal of American Medical Association 268(3):403-405, 1992.
129. 1993 Stahl SM. Mixed anxiety and depression: clinical implications. Journal of Clinical Psychiatry (suppl) 54(1):33-38, 1993.

PUBLICATIONS (13)

130. 1993 Stahl SM. Serotonergic mechanisms and the new antidepressants. Psychological Medicine 23:281-285, 1993.
131. 1993 Bronzo MR and Stahl SM. Galactorrhea induced by sertraline. Letter to the Editor, American Journal of Psychiatry 150(8):1269-1270, 1993.
132. 1993 Stahl SM, Hauger RL, Rausch JL, Fleishaker JC and Hubbell-Alberts EA. Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clinical Neuropharmacology 16(3):S19-S31, 1993.
133. 1993 Freedman DX and Stahl SM. Contempo 1993: Psychiatry. Journal of the American Medical Association 270(2):252-254, 1993.
134. 1993 Stahl SM. Alprazolam-XR: dosage considerations. Psychiatric Annals (suppl):27-31, 1993.
135. 1994 Stahl SM. New therapeutic advances in schizophrenia. In: Ancill R (Ed), Schizophrenia: Exploring the Spectrum of Psychosis, John Wiley & Sons Ltd., Sussex, 1994, pp. 137-152.
136. 1994 Stahl SM. Synaptic transmitters and neuromodulators. Ramachandran VS, (Ed). Encyclopedia of Human Behavior, Volume 4. Academic Press, San Diego, 1994, pp. 359-367.
137. 1994 Stahl SM and Hauger RL. Stress: An overview of the literature with emphasis on job-related strain and intervention. Advances in Therapy 11(3):110-119, 1994.
138. 1994 Stahl SM. Is serotonin receptor down regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacology Bulletin 30(1):39-43, 1994.
139. 1994 Gillin JC, Jernajczyk W, Valladares-Neto DC, Golshan S, Lardon M and Stahl SM. Inhibition of REM sleep by ipsapirone, A 5HT_{1A} agonist, in normal volunteers. Psychopharmacology 116:433-436, 1994.
140. 1995 Stahl SM. Targeting serotonin receptor subtypes as a strategy for the discovery of novel treatments in psychiatry (editorial). International Review of Psychiatry 7:3-4, 1995.
141. 1995 Stahl SM and Frakes DC. Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. International Review of Psychiatry 7:29-39, 1995.

PUBLICATIONS (14)

142. 1995 Kunovac JL and Stahl SM. Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. International Review of Psychiatry 7:55-67, 1995.
143. 1995 Rausch JL, LaFrance C and Stahl SM. Serotonin receptor-specific mediation of antidepressant treatment effects in depressed patients. International Review of Psychiatry 7:85-98, 1995.
144. 1995 Kunovac JL and Stahl SM. Future directions in anxiolytic pharmacotherapy. In: Pollack MH and Otto M, (Eds), The Psychiatric Clinics of North America 18(4):895-990, 1995.
145. 1995 Stahl SM and Soefje S. Panic attacks and panic disorder: the great neurologic imposters. In: Evans RW (Ed), Funny Spells, Seminars in Neurology 15(2):126-32, 1995.
146. 1995 Stahl SM and Kunovac JL. Neurotransmitter systems in obsessive compulsive disorder. In: Michaels R. (Eds). Psychobiological Foundations of Clinical Psychiatry, Psychiatry(3):64, Lippincott-Raven, Philadelphia, 1995, pp. 1-14.
147. 1996 Stahl SM. Phenomenology of anxiety disorders: clinical heterogeneity & comorbidity. In: Westenberg HGM, Murphy DL, and Den Boer JA (Eds), Advances in the Neurobiology of Anxiety Disorders, J. Wiley & Sons, Ltd., Chichester, U.K., Chapter 2, 1996, pp.21-38.
148. 1996 Seifritz E, Moore P, Trachsel, L, Bhatti T, Stahl SM and Gillin JC. The 5-HT_{1A} agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT₂ blockade. In: Neuroscience Letters 209:41-44, 1996.
149. 1996 Stahl SM. Diagnostic dilemmas in anxiety disorders. In: den Boer JA (Ed), Clinical Management of Anxiety; Theory and Practical Applications, Marcel Dekker Inc., New York, 1996, Chapter 2, pp 23-41.
150. 1996 Stahl, SM. Second messenger systems. Psychiatric Annals 26(4):183-184, 1996.
151. 1996 Stahl, SM. Two receptor superfamilies mediate fast and slow neurotransmission. Psychiatric Annals 26(5):244-253, 1996.
152. 1996 Stahl, SM. Beyond the second messenger: how molecular events mediate receptor downregulation. Psychiatric Annals 26(6):302-303, 1996.
153. 1996 Stahl, SM. The new antidepressants act by four distinct mechanisms. Psychiatric Annals 26(7):377-382, 1996.

PUBLICATIONS (15)

154. 1996 Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH and Cutler NR. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Journal of Clinical Psychiatry 57(7):287-291, 1996.
155. 1996 Gillin JC, Sohn WJ, Stahl SM, Lardon M, Kelsoe J, Rapaport M, Ruiz C and Golshan S. Ipsapirone, a 5HT_{1A} agonist, supresses REM sleep equally in depressed patients and normal controls. Neuropsychopharmacology 15(2):109-115, 1996.
156. 1996 Stahl, SM. Serotonin receptors. Psychiatric Annals 26(8):505-507,1996.
157. 1996 Stahl, SM. Immediate actions of SSRIs (serotonin selective reuptake inhibitors). Psychiatric Annals 26(9):564-565, 1996.
158. 1996 Stahl, SM. Long-term actions of SSRIs (serotonin selective reuptake inhibitors). Psychiatric Annals 26(10):626-627, 1996.
159. 1996 Stahl, SM. Serotonin pathways: mediators of SSRI (serotonin selective reuptake inhibitors) therapeutic actions. Psychiatric Annals 26(11):695-696, 1996.
160. 1996 Stahl SM. Serotonin pathways: mediators of SSRI side effects. Psychiatric Annals 26(12):738-742, 1996.
161. 1996 Sussman N and Stahl MS. Update in the pharmacotherapy of depression. The American Journal of Medicine (suppl)6A(101):26S-36S, 1996.
162. 1997 Stimmel GL, Dopheide JA, and Stahl SM. Mirtazapine: an antidepressant with selective alpha-2 adrenoceptor antagonist effects. Pharmacotherapy 17(1):10-21, 1997.
163. 1997 Stahl SM. Remeron (mirtazepine): a novel antidepressant that disinhibits serotonin and norepenephrine by alpha-2 antagonism. Psychiatric Annals 27(1):14-16, 1997.
164. 1997 Stahl SM. Remeron (mirtazapine): designing specific serotonergic actions. Psychiatric Annals 27(2):138-144, 1997.
165. 1997 Stahl SM. Glutamate: the universal excitatory neurotransmitter. Psychiatric Annals 27(3):152-155, 1997.
166. 1997 Stahl SM. Excitotoxicity: too much glutamate may be hazardous to your health. Psychiatric Annals 27(4):240-242, 1997.
167. 1997 Stahl SM. Apoptosis: neuronal death by design. Journal of Clinical Psychiatry 58(5):183-185, 1997.

PUBLICATIONS (16)

168. 1997 Stahl SM. The cytochrome P450 system Part 1: 1A2 and 2D6. Psychiatric Annals 27(6):400-402, 1997.
169. 1997 Stahl SM. Excitotoxicity and neuroprotection. Journal of Clinical Psychiatry 58(6):247-248, 1997.
170. 1997 Stahl SM and Sussman N. Mirtazapine: A Clinical Profile. Primary Psychiatry 4(6):83, 1997.
171. 1997 Stahl SM. The cytochrome P450 system Part 2: 3A3, 4. Psychiatric Annals 27(7):469-470, 1997.
172. 1997 Stahl SM. Mental illness may be damaging to your brain. Journal of Clinical Psychiatry 58(7):289-290, 1997.
173. 1997 Stahl SM, Zivkov M, Reimitz PE, and Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatrica Scandinavica (suppl) 391(96):22-30, 1997.
174. 1997 Stahl SM. Are two antidepressant mechanisms better than one? Journal of Clinical Psychiatry 58(8):339-341, 1997
175. 1997 Sambunaris A, Keppel Hesselink J, Pinder R, Panagides J, and Stahl SM. Development of new antidepressants. Journal of Clinical Psychiatry 58 (Suppl 6):40-53, 1997.
176. 1997 Stahl SM. Mixed depression and anxiety: serotonin 1A receptors as a common pharmacological link. Journal of Clinical Psychiatry 58 (Suppl 8):20-26, 1997.
177. 1997 Stahl SM. Amyloid cascade hypothesis of Alzheimer's disease. Psychiatric Annals 27(8):528-537, 1997.
178. 1997 Stahl SM. Neuroprotection: rescuing the brain from endogenous assassins. Psychiatric Annals 27(9):606-609, 1997.
179. 1997 Stahl SM. Selecting an antidepressant by matching patient profiles with antidepressant profiles. Psychiatric Annals 27(9):610-612, 1997.
180. 1997 Stahl SM. "Awakening" from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. Journal of Clinical Psychiatry 58(9):381-382.

PUBLICATIONS (17)

181. 1997 Seifritz E, Stahl SM and Gillin JC. Human sleep EEG following the 5-HT_{1A} antagonist pindolol: possible disinhibition of raphe neuron activity. Brain Research 759(1997): 84-91, 1997.
182. 1997 Stahl SM. Estrogen makes the brain a sex organ. Journal of Clinical Psychiatry 58(10): 421-422.
183. 1997 Stahl SM. Sex therapy for Psychiatrists has a new partner: reproductive hormones. Journal of Clinical Psychiatry 58(11): 468-469.
184. 1997 Stahl SM. Serotonin: It's possible to have too much of a good thing. Journal of Clinical Psychiatry 58(12): 520-521.
185. 1997 Stahl SM. Antidepressant combinations and augmentation strategies for difficult cases, Part 1: The serotonin strategy versus the classical strategies. Psychiatric Annals 27_(10): 657-660.
186. 1997 Lydiard RB, Stahl S, Hertzman M, and Harrison WM. A double-blind placebo-controlled study comparing the effects of sertraline with amitriptyline on quality of life in the treatment of major depression. Journal of Clinical Psychiatry 58: (11) 484-491, 1997.
187. 1997 Stahl SM. Reproductive hormones as adjuncts to psychotropic medication. Directions in Psychiatry, Volume 17: 303-314. The Hatherleigh Company, New York, 1997.
188. 1997 Stahl SM. Antidepressant combinations and augmentation strategies for difficult cases, Part 2: The heroic strategy. Psychiatric Annals 27: (11) 722-724.
189. 1997 Stahl SM. Treatments of Alzheimer's Disease: past, present and future. Psychiatric Annals 27: (12) 771- 772.
190. 1998 Bhatti T, Seifritz E, Clark C, Golshan S, Moore P, Stahl S, Rapaport M, Kelsoe J, Gillin JC. Effects of a tryptophan-free amino acid drink challenge on normal human sleep and EEG and mood. Biological Psychiatry 43:52-29, 1998.
191. 1998 Stahl SM. Brain Fumes: Yes, We Have NO Brain Gas. Journal of Clinical Psychiatry 59: (1) 6-7, 1998.
192. 1998 Stahl SM. Drug Combinations and Augmentation Strategies for Difficult Cases of Obsessive Compulsive Disorder. Psychiatric Annals 28:(1): 8-12.
193. 1998 Stahl SM. Drug Combinations and Augmentation Strategies for Difficult Cases of Panic Disorder. Psychiatric Annals 28: (2): 69-70, 1998.

PUBLICATIONS (18)

194. 1998 Stahl SM. How Psychiatrists can build new therapies for impotence. Journal of Clinical Psychiatry 59: (2): 47-48, 1998.
195. 1998 Stahl SM. Basic Psychopharmacology of Antidepressants (Part 1): Antidepressants have seven distinct mechanisms of action. Journal of Clinical Psychiatry 59: (Suppl.4) 5-14, 1998.
196. 1998 Stahl SM. Basic Psychopharmacology of Antidepressants (Part 2): Estrogen as an adjunct to antidepressant treatment. Journal of Clinical Psychiatry 59: (Suppl.4) 15-24, 1998.
197. 1998 Stahl SM. Nitric Oxide Physiology and Pharmacology. Journal of Clinical Psychiatry 59:(3) 101-102, 1998.
198. 1998 Stahl SM. Brain Tonics for Brain Sprouts: How Neurotrophic Factors Fertilize Neurons. Journal of Clinical Psychiatry 59: (4) 149-150, 1998.
199. 1998 Stahl SM. Recognition Molecules Are Trailblazers for Axon Pathways. Journal of Clinical Psychiatry 59: (5) 215-216, 1998.
200. 1998 Stahl SM, Kaiser L, Roeschen J, Keppel Hesselink JM, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int. Journal of Neuropsychopharmacology. Vol.1, No.1, 11-18, 1998.
201. 1998 Stahl SM. When Neurotrophic Factors get on your nerves: therapy for neurodegenerative disorders. Journal of Clinical Psychiatry. 59: (6) 277-278, 1998.
202. 1998 Stahl SM. Not So Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychiatry. 59: (7) 343-344, 1998.
203. 1998 Stahl SM. What Makes An Antipsychotic Atypical. Journal of Clinical Psychiatry. 59: (8) 403-404, 1998.
204. 1998 Seifritz E, Gillin JC, Kelsoe JR, Rapaport MH, Bhatti T and Stahl SM. Sleep EEG response to muscarinic and Serotonin _{1A} Receptor Probes in Patients with Major Depression and in Normal Controls. Biological Psychiatry 4 (7): 21-33, 1998.
205. 1998 Stahl SM. Neuropharmacology of Obesity: My Receptors Made Me Eat It. Journal of Clinical Psychiatry. 59: (9) 447-448, 1998.
206. 1998 Stahl SM. How To Appease the Appetite of Psychotropic Drugs. Journal of Clinical Psychiatry. 59: (10) 500-501.

PUBLICATIONS (19)

207. 1998 Stahl SM. Enhancing Cholinergic neurotransmission with the new cholinesterase inhibitors: implications for Alzheimer's Disease and Cognitive Disorders. Hospital Practice. Vol. 33 No. 11, 131-136.
208. 1998 Stahl SM. Selecting an antidepressant using mechanism of action to enhance efficacy and avoid side effects. Journal of Clinical Psychiatry. 59: (Suppl. 18) 23-29.
209. 1998 Stahl SM. Augmentation of antidepressants by Estrogen. Psychopharmacology Bulletin. 34 (3): 319-321.
210. 1998 Moore PJ, Gillin JC, Bhatti T, Seifritz E, Clark C, Stahl SM, Kelsoe J and Rapaport M. Rapid tryptophan depletion affects sleep EEG but not mood in fully remitted and depressed patients on serotonin reuptake inhibitors. Archives of General Psychiatry. 55: (6) 534-539.
211. 1998 Stahl SM. Getting Stoned Without Inhaling: Anandamide is the Brain's Natural Marijuana. Journal of Clinical Psychiatry. 59 (11): 566-567.
212. 1998 Stahl SM. Using Secondary Binding Properties to Select a Not So Selective Serotonin Reuptake Inhibitor. Journal of Clinical Psychiatry. 59 (12): 642-643.
213. 1998 Stahl SM. Mechanism of Action of Serotonin Selective Reuptake Inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects (mechanism of action of SSRIs). Journal of Affective Disorders 12: 51 (3) 215-235.
214. 1999 Stahl SM. Peptides and Psychiatry, Part 1: How Synthesis of Neuropeptides Differs from Classical Neurotransmitter Synthesis. Journal of Clinical Psychiatry. 60 (1): 5-6.
215. 1999 Stahl SM. Substance P and the Neurokinins, Part 2: Novel Peptide Neurotransmitters in Psychopharmacology. Journal of Clinical Psychiatry. 60 (2): 77-78.
216. 1999 Stahl SM. Peptides and Psychiatry, Part 3: Substance P and Serendipity: Novel Psychotropics Are A Possibility. Journal of Clinical Psychiatry. 60 (3): 140-141.
217. 1999 Stahl SM. Why Settle For Silver, When You Can Go for Gold? Response vs. Recovery as the Goal of Antidepressant Therapy. Journal of Clinical Psychiatry 60: (4) 213-214.

PUBLICATIONS (20)

218. 1999 Stahl SM. Mergers and Acquisitions Among Psychotropics: Antidepressant Takeover of Anxiety May Now Be Complete. Journal of Clinical Psychiatry 60: (5) 282-283.
219. 1999 Stahl SM (Editor). What Makes An Antipsychotic Atypical? Journal of Clinical Psychiatry 60 (Supplement 10).
220. 1999 Stahl SM. Selecting An Atypical Antipsychotic by Combining Clinical Experience With Guidelines From Clinical Trials. Journal of Clinical Psychiatry. 60 (Supplement 10): 31-41.
221. 1999 Stahl SM. Antidepressants: The Blue-Chip Psychotropic for the Modern Treatment of Anxiety Disorders. Journal of Clinical Psychiatry. 60: (6) 356-357.
222. 1999 STAHL SM. Antipsychotic Polypharmacy, Part I: Therapeutic Option or Dirty Little Secret? Journal of Clinical Psychiatry. 60: (7) 425-426.
223. 1999 Stahl SM. Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. Journal of Clinical Psychiatry.60: (8) 506-507.
224. 1999 Shelton RC, Simon GE, Stahl SM, Treisman GJ and Williams JW. Fine Tuning the Treatment of Depression. Patient Care, Vol. 13, No. 13, 181-197.
225. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 1, Overview of Gene Activation by Neurotransmitters. Journal of Clinical Psychiatry. 60: (9) 572-573.
226. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 2: How Neurotransmitters Activate Second Messenger Systems. Journal of Clinical Psychiatry. 60: (10) 647-648.
227. 1999 Stahl SM. Reply to Masand P: "Relative Weight Gain Among Antipsychotics". Journal of Clinical Psychiatry. 60: (9) 707-708.
228. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 3: How Second Messengers "Turn On" Genes by Activating Protein Kinases and Transcription Factors. Journal of Clinical Psychiatry. 60: (11) 731-732.
229. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 4: Transferring the Message of Chemical Neurotransmission From Presynaptic Neurotransmission to Postsynaptic Gene Expression. Journal of Clinical Psychiatry. 60: (12) 813-814.

PUBLICATIONS (21)

230. 1999 Settle EC, Stahl SM, Batey SR, Johnston JA, and Ascher JA. Safety and tolerability of the sustained-release form of bupropion in depression: a review of results of three clinical trials. Clinical Therapeutics Volume 31; (3): 454-463, 1999.
231. 2000 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 5: How a Leucine Zipper Can Turn On Genes: Immediate-Early Genes Activate Late-Gene Expression in the Brain. Journal of Clinical Psychiatry. 61: (1) 7-8.
232. 2000 Stahl SM and Kunovac JL. Serotonin-Specific Anxiolytics: Now and in the Future. In: Montgomery S and Halbreich U, (Eds), Pharmacotherapy of Mood and Cognition, American Psychiatric Press, Inc., Washington,DC, 2000, pp. 355-366.
233. 2000 Stahl SM, Judd LL and Kunovac JL. Overview of New Anxiolytics: In: Montgomery S and Halbreich U, (Eds), Pharmacotherapy of Mood and Cognition, American Psychiatric Press, Inc. Washington, D.C.,2000, pp. 333-340.
234. 2000 Stahl SM. Blue Genes and the Monoamine Hypothesis of Depression. Journal of Clinical Psychiatry. 61: (2)77-78.
235. 2000 Stahl SM. Blue Genes and the Mechanism of Action of Antidepressants. Journal of Clinical Psychiatry. 61:(3) 164-165.
236. 2000 Stahl SM and Shayegan D. New Discoveries In The Development of Antipsychotics With Novel Mechanisms of Action: Beyond The Atypical Antipsychotics With Serotonin Dopamine Antagonism. In: Atypical Antipsychotics (MDT)/ed. by B.A. Ellenbroek and A.R. Cools, pp. 215-232, 2000.
237. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists. Journal of Clinical Psychiatry. 61: (4) 242-243.
238. 2000 Hoehn-Saric R, Ninan P, Black D, Stahl SM, Griest J, Lydiard B, McElroy S, Zajecka J, Harrison W, Clary C, Chapman D. Multicenter Double-Blind Comparison of Sertraline vs. Desipramine for Concurrent Obsessive-Compulsive Disorder and Major Depressive Disorder. Archives of General Psychiatry, Vol. 57, January, 76- 82, 2000.
239. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists,Part 2: Begin with the End in Mind. Journal of Clinical Psychiatry. 61: (5) 327-328.
240. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists. Part 3: Sharpen the Saw with Selective Choices of Continuing Medical Education Programs. Journal of Clinical Psychiatry 61 (6): 401-402.

PUBLICATIONS (22)

241. 2000 Stahl SM. Gold vs. Silver: the issue of functional vs. symptomatic recovery in depression (Pradham). Journal of Clinical of Psychiatry. 61: (6) 447-448.
242. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists, Part 4: Developing and Implementing the Vision. Journal of Clinical Psychiatry. 61: 7, 464-465.
243. 2000 Stahl SM. Polypharmacy of Two Atypical Antipsychotics. Letter to the Editor #2155. Journal of Clinical Psychiatry. 61: (9), 679-680.
244. 2000 Stahl SM. Paying Attention to Your Acetylcholine, Part I: Structural Organization of Nicotinic Receptors. Journal of Clinical Psychiatry. 61: (8), 547-548.
245. 2000 Stahl SM. Paying Attention to Your Acetylcholine, Part 2: The Function of Nicotinic Receptors. Journal of Clinical Psychiatry. 61: (9), 628-629.
246. 2000 Shayegan D and Stahl SM. Buspirone. In: Briley and Nutt (eds.) Milestones in Drug Therapy - Anxiolytics. Birkhauser Verlag, Basel, Boston, Berlin, 2000, pages 13-25.
247. 2000 Stahl SM. Placebo-Controlled Comparison of the Selective Serotonin Reuptake Inhibitors Citalopram and Sertraline. Biological Psychiatry Vol. 48, pages 894-901.
248. 2000 Stahl SM. The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 1 "Their Similarities Are Different". J. Clin.Psychiatry 61: (10), 710-711.
249. 2000 Stahl SM. Commentary on the limitation of antidepressants in current use. In: Antidepressants, edited by B. E. Leonard, Birkhauser Verlag Basel 2001, pages 31-43.
250. 2000 Stahl SM. The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 2: Illustrating Their Mechanisms of Action. J.Clin.Psychiatry 61: (11), 813-814.
251. 2000 Stahl SM. New Drug Discovery in the Postgenomic Era: From Genomics to Proteomics" J of Clinical Psychiatry 61: (12), 894-895.
252. 2000 Stein DJ and Stahl SM. Serotonin and Anxiety: Current Models. International Clinical Psychopharmacology, 2000; 2000: S1-6.
253. 2001 Shelton RC, Tollefson GD, Tohen M, Gannon KS, Jacobs T, Buras W, Bymaster FP, Zhang W, Spencer K, Feldman PD, Stahl SM and Meltzer HY. A Novel Augmentation Strategy for Treatment-Resistant Major Depression. Am J Psychiatry 2001; 158: 131-134.

PUBLICATIONS (23)

254. 2001 Stahl SM. Does Evidence From Clinical Trials in Psychopharmacology Apply in Clinical Practice? Journal Of Clinical Psychiatry 62: (1), p 6-7.
255. 2001 Ferguson, JM, Sahrivastava RK, Stahl SM, Hartford JT, Borian F, Leni John, McQuade RD, and Jody D. Re-emergence of Sexual Dysfunction in Patients with Major Depressive Disorder: Double-Blind Comparison of Nefazodone and Sertraline. Journal of Clinical Psychiatry 62: (1) 24-29.
256. 2001 Stahl SM, Nierenberg A and Gorman J. Evidence of Early Onset of Antidepressant Effect in Randomized Controlled Trials. J. Clinical Psychiatry, Vol 62, Supplement 4, p. 17-23.
257. 2001 Stahl SM. The Psychopharmacology of Sex: Part 1. Neurotransmitters and the 3 Phases of the Human Sexual Response. Journal of Clinical Psychiatry 62: (2) 80-81
258. 2001 Leon A, Blier P, Culpepper L, Gorman J, Hirschfeld R, Nirenberg A, Roose S, Rosenbaum J, Stahl SM and Trivedi M. An Ideal Trial to Test Differential Onset of Antidepressant Effect. Journal of Clinical Psychiatry, Vol. 62; Supplement 4, p. 34-36.
259. 2001 Stahl SM. The Psychopharmacology of Sex, Part 2. Effects of Drugs and Disease on the 3 Phases of Human Sexual Response. Journal of Clinical Psychiatry, 62: (3), P. 147-148.
260. 2001 Shelton RC, Keller MB, Gelenberg A, Dunner DL, Halbreich U, Hirschfeld R, Thase ME, Russel J, Lydiard RB, Crits-Cristophe P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G and Stahl SM. The Effectiveness of St. John's Wort in Major Depression: A Multi-Center Randomized Placebo Controlled Trial. The Journal of the American Medical Association 2001; 285: 1978-1986.
261. 2001 Hirschfeld RMA, Nierenberg A, Gorman JM, Roose SP, Leon AC, Blier P, Culpepper L, Rosenbaum JF, Stahl SM and Trivedi MH. Do Some Antidepressants Have a Faster Onset of Action Than Others? A Debate and Discussion. Journal Of Clinical Psychiatry, Vol. 62; Supplement 4, p. 37-40.
262. 2001 Stahl SM and Klitgaard H. New Developments in the Treatment of Epilepsy. A Teaching Monograph. CNS Spectrums, Volume 6 – Number 4 (suppl 2), April 2001.
263. 2001 Stahl SM. Why Drugs and Hormones May Interact in Psychiatric Disorders. J Clin Psychiatry 62: 4, 225-226.
264. 2001 Stahl SM. Effects of Estrogen on the Central Nervous System. J Clin Psychiatry 62: 5, p 317-18.

PUBLICATIONS (24)

265. 2001 Stahl SM. Sex and Psychopharmacology: Is Natural Estrogen a Psychotropic Drug in Women? Commentary on “Efficacy of Estradiol for the treatment of depressive disorders in perimenopausal women”. Archives of General Psychiatry, Vol 58, June; 537-538.
266. 2001 Stahl SM. Natural Estrogen as an Antidepressant for Women. Journal of Clinical Psychiatry, 62: 6, 404-405.
267. 2001 Stahl SM. Reply to Burt and Lane: Comparisons between two SSRIs their similarities are different. Biological Psychiatry, 50: 66-69.
268. 2001 Stahl SM. Fibromyalgia: The Enigma and the Stigma. Journal of Clinical Psychiatry, 62: (7), 501-502.
269. 2001 Stahl SM. Psychopharmacology of antidepressants – Ideal Therapy adds some mechanisms and subtracts some others. Japanese Journal of Clinical Psychopharmacology Vol. 4, no. 8, August 2001, p. 102-118.
270. 2001 Stahl SM. Gut Feelings About Irritable Bowel Syndrome. Journal of Clinical Psychiatry, 62: (8) 590-591.
271. 2001 Stahl SM. “Hit and Run” Actions at Dopamine Receptors, Part 1: Mechanism of Action of Atypical Antipsychotics. J Clin Psy 62 (9) 670-671.
272. 2001 Moore, P, Seifritz E, Schlosser A, Greenfield D, Stahl SM, Rapaport M and Kelsoe J. Rapid Tryptophan Depletion Plus a Serotonin 1A agonist: Competing Effects on Sleep in Healthy Men. Neuropsychopharmacology, Vol. 25, No. S5, p. S39-S44
273. 2001 Stahl SM. “Hit and Run” Actions at Dopamine Receptors, Part 2: Illustrating Fast Dissociation From Dopamine Receptors That Typifies Atypical Antipsychotics. J Clin Psychiatry 62 (10) 747-748
274. 2001 Stahl SM. Dopamine System Stabilizers, aripiprazole, and the Next Generation of antipsychotics Part 1 “Goldilocks” Actions at Dopamine Receptors. J Clin Psychiatry 62 (11) 841-842.
275. 2001 Stahl SM. Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 2. Illustrating Their Mechanism Of Action. J Clin Psychiatry 62 (12) 923-924.
276. 2002 Stahl SM. The Psychopharmacology of Energy and Fatigue. J Clin Psych 63: (1) 7-8.
277. 2002 Stahl SM. Antipsychotic Polypharmacy: Squandering Precious Resources? Journal of Clinical Psychiatry 63 (2); 93-94.

PUBLICATIONS (25)

278. 2002 Stahl SM. Selective Actions on Sleep or Anxiety by Exploiting GABA-A/Benzodiazepine Receptor Subtypes. Journal of Clinical Psychiatry 63: (3) 179-180.
279. 2002 Stahl SM Does Depression Hurt? Journal of Clinical Psychiatry 63: (4): 273-274.
280. 2002 Stahl SM and Niculescu AB. Molecular Biology Research in Psychiatry. In: Psychiatry as a Neuroscience, John Wiley and Sons Ltd.
281. 2002 Stahl SM. The Psychopharmacology of Painful Physical Symptoms in Depression. J. Clin. Psychiatry 63: (5) 382-383.
282. 2002 Stahl SM. Awakening to the Psychopharmacology of Sleep and Arousal: Novel Neurotransmitters and Wake-Promoting Drugs. J. Clin Psychiatry 63: (6) 467-468.
283. 2002 Stahl SM. Psychopharmacology of Wakefulness: Pathways and Neurotransmitters. J Clin Psychiatry 63: (7) 551-552.
284. 2002 Stahl SM, Mendels J and Schwartz G. Effects of Reboxetine on Agitation, Anxiety and Insomnia: Results of a Pooled Evaluation of Randomized Clinical Trials. Journal Of Clinical Psychopharmacology Vol 22, No. 4, p. 388-392.
285. 2002 Stahl SM. Mirror, Mirror on the Wall, Which Enantiomer Is Fairest of Them All? J Clin Psychiatry 63: (8) 656-657.
286. 2002 Stahl SM. Antipsychotic Polypharmacy: Evidence Based or Eminence Based? Acta Psychiatrica Scandinavica Vol 106 No 5, 321-322.
287. 2002 Stahl SM. Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder. J Clin Psychiatry 63: (9) 756-757.
288. 2002 Stahl SM. Independent Actions on Fear Circuits May Lead to Therapeutic Synergy for Anxiety When Combining Serotonergic and GABAergic Agents. J Clin Psychiatry 63: 10, 854-855.
289. 2002 Lutz W, Stahl SM, Howard KI and Grissom GR. Some Relationships among assessments of depression, Journal of Clinical Psychology. Vol 58 (12), 1545-1553
290. 2002 Stahl SM. Can Psychopharmacologic Treatments That Relieve Symptoms Also Prevent Disease Progression? J Clinical Psychiatry 63: 11, 961- 962.

PUBLICATIONS (26)

291. 2002 Stahl SM, Entsuah AR and Rudolph RL. Comparative Efficacy Between Venlafaxine and SSRIs: A Pooled Analysis of Patients with Depression. Biological Psychiatry, 52 (12): 1166-1174, 2002.
292. 2002 Stahl M. The Metabolic Syndrome: Psychopharmacologists Should Weigh the evidence for Weighing the Patient. J. Clin Psychiatry 63: 12, 1094 – 1095.
293. 2003 Stahl SM. Reply to Welch R and Snaterse M. Combination Therapy: Is Clinical Practice Leading the Way or Are We Following the Pied Piper? J Clin Psychiatry. 64 (1): 94-96.
294. 2003 Stahl SM. Neurotransmission of Cognition, Part 1 Dopamine is a Hitchhiker in Frontal Cortex: Norepinephrine Transporters Regulate Dopamine. J Clinical Psychiatry 64: 1, 4-5.
295. 2003 Hollander E, Kaplan A and Stahl SM. A double-blind, placebo controlled trial of clonazepam in obsessive-compulsive disorder. World J Bio Psychiatry 4 (1): 30-34.
296. 2003 Stahl SM. Neurotransmission of Cognition, Part 2 Selective SRIs Are Smart Drugs: Regionally Selective Actions on Both Dopamine and Norepinephrine to Enhance Cognition. J. Clinical Psychiatry 64: 2, 110-111.
297. 2003 Stahl SM. Neurotransmission of Cognition, Part 3 Mechanism of Action of Selective NRIs: Both Dopamine and Norepinephrine Increase in Prefrontal Cortex. J Clin Psychiatry 64:3, 230-231.
297. 2003 Stahl SM. Neurotransmission of Cognition, Part 3 Mechanism of Action of Selective NRIs: Both Dopamine and Norepinephrine Increase in Prefrontal Cortex. J Clin Psychiatry 64:3, 230-231.
298. 2003 Stahl SM, Markowitz PH, Gutterman EM and Papadopoulos G. Co-Use of Donepezil and Hypnotics Among Alzheimer's Disease Patients Living in the Community. Journal of Clinical Psychiatry 64: 4, 466-472.
299. 2003 Stahl SM. At Long Last, Long-Lasting Psychiatric Medications: An Overview of Controlled Release Technologies. J. Clinical Psychiatry 64: 4, 355-356.
300. 2003 Stahl SM. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. The Primary Care Companion J Clin Psychiatry 5 (Suppl 3) 9-13.
301. 2003 Stahl SM. The Ups and Downs of Novel Antiemetic Drugs, Part 1 Substance P, 5-HT, and the Neuropharmacology of Vomiting. J Clin Psychiatry 64 5, 498-499.

PUBLICATIONS (27)

302. 2003 Stahl SM. The Ups and Downs of Novel Antiemetic Drugs, Part 2: An Illustration. J Clin Psychiatry 64: 6, 626-627.
303. 2003 Stahl SM. Antidepressants and Somatic Symptoms: Therapeutic Actions Are Expanding Beyond Affective Spectrum Disorders To Functional Somatic Syndromes. J Clin Psychiatry 64: 7, 745-746.
304. 2003 Stahl SM. Here Today and Not Gone Tomorrow: The Curse of Chronic Pain and Other Central Sensitization Syndromes. J. Clin Psychiatry 64: 8, 863-864.
305. 2003 Damatarca C, Stahl SM. Pain and Depression: Bridging the Body and Mind. Depression: Mind and Body. Volume 1, Number 1, p. 7-13.
306. 2003 Stahl SM. Deconstructing Psychiatric Disorders, Part 1: Genotypes, Symptom Phenotypes, and Endophenotypes. J. Clin Psychiatry 64: 9, 982-983.
307. 2003 Stahl SM. Reply to Freudenreich and Goff "Polypharmacy in Schizophrenia: A Fuzzy Concept". Journal of Clinical Psychiatry 64: 9, 1132-1133.
308. 2003 Stahl SM, Grady MM. Mechanism of Action Differences Between Current Antidepressants and those soon to be released. J. Clin Psych 64 (Suppl 13) 13-17.
309. 2003 Stahl SM. Key Issues and Unmet Needs in Schizophrenia. In: Dopamine in the Pathophysiology and Therapeutics of Schizophrenia: New Findings, New Directions. Eds: Shitij Kapur and Yves Lecrubier, pages 237-252.
310. 2003 Stahl SM. Deconstructing Psychiatric Disorders, Part 2: An Emerging, Neurobiologically Based Therapeutic Strategy for the Modern Psychopharmacologist. J. Clin Psych 64: 10, 1145-1146.
311. 2003 Stahl SM, Gergel I and Li D. Escitalopram in the Treatment of Panic Disorder: A Randomized, Double Blind, Placebo-Controlled Trial. Journal of Clinical Psychiatry 64: 11, 1322-1327.
312. 2003 Stahl SM, Zhang L, Damatarca C, Grady MM. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue and executive dysfunction in major depressive disorder. J Clin Psychiatry 64: (Suppl 4) 6-17.
313. 2003 Stahl SM. Symptoms and Circuits, Part 1, Major Depressive Disorder. J Clin Psychiatry 64: 11, 1282-1283.
314. 2003 Stahl SM. Symptoms and Circuits, Part 2: Anxiety Disorders. J.Clin Psychiatry 64: 12,1408-1409.

PUBLICATIONS (28)

315. 2003 Stahl SM and Shayegan D. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003 64 (supplement 19):6-12.
316. 2004 Stahl SM. Symptoms and Circuits, Part 3: Schizophrenia. J. Clin Psychiatry 65: 1, 8-9.
317. 2004 Stahl SM, Markowitz JS, Papadopoulos G. Examination of nighttime sleep related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research and Opinion. Vol. 20, No. 4, p. 517-524.
318. 2004 Stahl SM. Psychopharmacology of Anticonvulsants: Do All Anticonvulsants Have the Same Mechanism of Action? J Clin Psych 65: 2, 149-150.
319. 2004 Damatarca C, Stahl J and Stahl SM. Psychopharmacologic Approaches to the Treatment of Anxiety. Drug Ben Trends, Volume 16, No. 2, 94-100.
320. 2004 Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Cur Med Chem, 11, 313-326.
321. 2004 Stahl SM. Anticonvulsants as Anxiolytics, Part 1: Tiagabine and other Anticonvulsants With Actions on GABA, J Clin Psych 65:3, 291-292.
322. 2004 Stahl SM, Nicolescu AB and Grady MM. Developments in Antidepressants. In: Advances on Management and treatment of Depression. Eds: Michael Thase and John Potokar.
323. 2004 Stahl SM. Anticonvulsants as Anxiolytics, Part 2: Pregabalin and Gabapentin as $\alpha\delta$ Ligands at Voltage-Gate Calcium Channels. J. Clinical Psychiatry 65: 4, 460-461.
324. 2004 Stahl SM. Focus: antipsychotic polypharmacy – evidence based prescribing or prescribing based evidence? Int J Neuropsychopharmacol 2004;7(2):113-6.
325. 2004 Stahl SM, Grady MM. Estrogen as an Antidepressant. Trends in Evidence-Based Neuropsychiatry (TEN) 6 (1): 23-27.
326. 2004 Stahl SM. Anticonvulsants and the Relief of Chronic Pain: Pregabalin and Gabapentin as Ligands at Voltage Gated Calcium Channels. J Clin Psychiatry 65:5, 396-397.
327. 2004 Stahl SM. Anticonvulsants as Mood Stabilizers and Adjuncts to Antipsychotics: Valproate, Lamotrigine, Carbamazepine, and Oxcarbazepine and Actions at Voltage-Gated Sodium Channels. J.Clin Psychiatry 65: 6, 738-739.

PUBLICATIONS (29)

328. 2004 Stahl SM. Mechanism of Action of Voltage Sensitive Sodium Channel Modulators. J Clin Psychiatry 65: 7, 894-895.
329. 2004 Gelenberg AF, Shelton RC, Crits-Cristoph P, Keller MB, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM and Halbreich U. The effectiveness of St. John's Wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. Journal of Clinical Psychiatry 2004;65(8):1114-9.
330. 2004 Stahl SM, Pradko J. A Review of the Neuropharmacology of Bupropion SR: A Dual NE and DA Reuptake Inhibitor. Journal of Clinical Psychiatry Primary Care Companion. Volume 6, (4) 159-166.
331. 2004 Stahl SM. Mechanism of Action of Alpha 2 Delta Ligands: Voltage Sensitive Calcium Channel (VSCC) Modulators. Journal of Clinical Psychiatry 65: 8, 1033-1034.
332. 2004 Stahl SM, Freudenreich O, Goff DC. A Successful Antipsychotic Combination Trial. Quo Vadis? Acta Psychiatrica Scand 2004: 110: 241-242.
333. 2004 Stahl SM and Briley M. Understanding pain in depression. Human Psychopharmacology Clin Exp (suppl)19: S9-S13.
334. 2004 Stahl SM. Psychopharmacology of Anticonvulsants: Levetiracetam as A Synaptic Vesicle Protein Modulator. J. Clin. Psychiatry 65: 9, 1162-1163.
335. 2004 Stahl SM. Selectivity of SSRIs: individualizing patient care through rational treatment choices. Int J Psy Clin Prac, Volume 8, (Suppl 1), Pages 3-10.
336. 2004 Stahl SM. Drug Combinations for Bipolar Spectrum Disorders: Evidence-Based Prescribing or Prescribing Based Evidence? Journal Clinical Psychiatry 65: 10, 1298-1299
337. 2004 Stahl SM. Prophylactic Antipsychotics: Do They Keep You From Catching Schizophrenia? J Clin Psychiatry 65: 11, 1445-1446.
338. 2004 Stahl SM, Shayegan DK. Novel mechanisms of Action: Beyond atypical antipsychotics... in den Boer JA, ter Horst GJ and George M, Current and Future Developments in Psychopharmacology, Benecke, Amsterdam, p. 287-315.
339. 2004 Shayegan DK and Stahl SM. Atypical Antipsychotics: Matching Receptor Profile to Individual Patient's Clinical Profile. CNS Spectrums Oct; 9 (10 Suppl 11): p. 6-14
340. 2004 Stahl SM. Preemptive Analgesia: Is Pain Less Costly When You Pre-Pay For It? J Clin Psychiatry 65:12, 1591-1592.

PUBLICATIONS (30)

341. 2004 Shelton RC and Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression, Journal of Clinical Psychiatry 65(12):1715-19.
342. 2005 Stahl SM. Is Psychopharmacologic "Inoculation" Effective in Preventing Posttraumatic Stress Disorder? J Clin Psychiatry 66: (1): 5-6.
343. 2005 Grady MM, Stahl SM. Panic Attacks and Panic Disorders: the great imitators. In: Imitators of Epilepsy, second edition. Ed: Kaplan PW, Fisher RS. Demos Medical Publishing, p. 277-288.
344. 2005 Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacology, 8, 93-105.
345. 2005 Citrome L, Goldberg FJ and Stahl SM. Towards convergence in the medication treatment of bipolar disorder and schizophrenia. Harvard Rev Psychiatry, Volume 13, Number 1, January/February 2005, 28-42.
346. 2005 Stahl SM. Antidepressant treatment of psychotic depression: the role of the sigma receptor. CNS Spectrums, Volume 10, Number 4, 319-323.
347. 2005 Fava M, Rush JA, Thase ME, Clayton A, Stahl SM, Pradko JF and Johnston JA. 15 years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. Primary Care Companion, 7: (3); 106-113.
348. 2005 Shayegan DS and Stahl SM. Emotion Processing, the Amygdala, and Outcome In Schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29: 840-845.
349. 2005 Stahl SM, Grady MM, Moret C, Briley M. Serotonin and norepinephrine reuptake inhibitors (SNRIs): A review of their pharmacology, clinical efficacy and tolerability in comparison to other classes of antidepressant. CNS Spectrums, Sept; 10 (9): 732-747.
350. 2005 Stahl SM. Possible Antipsychotic Effect of Fluvoxamine. Response to Letter to the Editor, CNS Spectrums, Volume 10 (10): 774-775.
351. 2006 Stahl SM. Finding What You Are Not Looking For: Strategies for Developing Novel Treatments in Psychiatry. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics, Volume 3, No. 1, 3-9.
352. 2006 Stahl SM. Finding Better Answers for Sleep Disorders. Current Psychiatry Vol 5, No.1, January 2006 p. 68-70.

PUBLICATIONS (31)

353. 2006 Stahl SM, Grady M. High Cost Use of Second-Generation Antipsychotics under California's Medicaid Program. Psychiatric Services, Volume 57, Issue 1, p. 127-129.
354. 2006 Stahl SM. A rash proposal for treating bipolar disorder. Current Psychiatry Vol 5, No. 2, p. 92-100.
355. 2006 Stahl SM. What's Wrong with Multicenter Trials. Current Psychiatry Vol. 5, No. 3,, p. 37-41.
356. 2006 Rausch JL; Johnson ME; Kasik KE and Stahl SM. Temperature Regulation in Depression: Functional 5HT1A Receptor Adaptation Differentiates Antidepressant Response. Neuropsychopharmacology, 31, 2274-2280.
357. 2006 Stahl SM; Grady M; Santiago G; and Davis RL. Optimizing Outcomes in Psychopharmacology Continuing Medical Education (CME): Measuring Learning And Attitudes That May Predict Knowledge Translation into Clinical Practice. FOCUS Vol IV, No. 4, 487-495.
358. 2007 Stahl SM and Buckley PF. Negative Symptoms of Schizophrenia: a problem that will not go away. Acta Scandinavia Psychiatria 2007: 115: 4-11.
359. 2007 Buckley PF and Stahl SM. Pharmacological Treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-Sac? Acta Scandinavia Psychiatria 2007: 115: 93-200.
360. 2007 Stahl SM. Overview of Trends in Modern Psychopharmacology. CNS Spectrums 12: 2, 103-105.
361. 2007 Stahl SM Monoamine mechanisms in pain and depression. Neuropsychiatric Disease and Treatment 3 (Suppl 1) 9-12.
362. 2007 Stahl SM. Beyond the dopamine hypothesis to the NMDA Glutamate Receptor Hypofunction Hypothesis of Schizophrenia. CNS Spectrums 12: 4, 265-268.
363. 2007 Stahl SM. Novel Therapeutics for Schizophrenia: Targeting Glycine Modulation of NMDA Glutamate Receptors. CNS Spectrums 12:6 423-427.
364. 2007 Rollema H, Coe J, Chambers L, Hurst R, Stahl SM and Williams K. Alpha 4 Beta 2 nicotinic acetylcholine receptor partial agonists for the treatment of nicotine dependence: rationale, pharmacology and clinical efficacy. Trends in Pharmacological Science 28 (7): 316-325.

PUBLICATIONS (32)

365. 2007 Stahl SM. A Different Mechanism to Understand Activation/Sedation Side Effects of Ziprasidone. Response Letter to the Editor. Journal of Clinical Psychiatry 68: 6, 975-976.
366. 2007 Stahl SM. Genetics of Schizophrenia converge on the NMDA receptor. CNS Spectrums 12; 8, 583-588.
367. 2007 Stahl SM. Novel Therapeutics for Depression: L-methylfolate (6 (S)-5 methyltetrahydrofolate or MTHF) as a Trimonoamine Modulator and Antidepressant Augmenting Agent. CNS Spectrums 12, 10, 423-428.
368. 2007 Gharabawi GM; Rupnow MFT; Greenspan A; Kosik-Gonzalez C; Young Z and Stahl SM. Incidence and costs of polypharmacy: data from a randomized, double-blind study of risperidone and quetiapine in patients with schizophrenia and schizoaffective disorder. Current Medical Research and Opinion 23; 11, 2815-2822.
369. 2007 Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. International Journal of Neuropsychopharmacology 10, 575-578.
370. 2007 Nutt D; Demyttenaere K; Janka Z; Aare T; Bourin M; Canonico PL; Carrasco JL and Stahl SM. The Other Face of Depression, reduced positive affect: the role of catecholamines in causation and cure. Journal of Psychopharmacology 21; 5, 461-471.
371. 2007 Stahl SM; Ahmed S; Haudiquet V. Analysis of the Rate of Improvement of Specific Psychic and Somatic Symptoms of General Anxiety Disorder During Treatment With Venlafaxine ER. CNS Spectrums 2; 9, 703-711.
372. 2008 Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Sasntucci V, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, LeFur G and Griebel G. Stimulation of the Beta-3 adrenoceptor as a novel treatment for anxiety and depression disorders". Neuropsychopharmacology 33: 574-587.
373. 2008 Buckely P and Stahl SM. Letter to the Editor. Reply to: Repetitive transcranial magnetic stimulation as new technique for treatment of negative symptoms of schizophrenia. Acta Psychiatr Scand 117: 1, 79.
374. 2008 Zisook S, Glick I, Jefferson J, Wagner, K, Salzman C, Peselow E and Stahl S. Teaching Psychopharmacology: What Works and What Doesn't. Journal of Clinical Psychopharmacology 28 (1): 96-100 February 2008.
375. 2008 Stahl SM. Personalized Medicine, Pharmacogenomics, and the Practice of Psychiatry: On the Threshold of Predictive Therapeutics in Psychopharmacology? CNS Spectrums 13: 2, 115-118.

PUBLICATIONS (33)

376. 2008 Stahl SM. Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics? CNS Spectrums 13:4, 279-282.
377. 2008 Stahl SM and Wise DD. The Potential Role of a Corticotropin-Releasing Factor Receptor-1 antagonist in Psychiatric Disorders. CNS Spectrums, 13:6, 467-483.
378. 2008 Wise D, Felker A and Stahl SM. Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology. CNS Spectrums 13: 8, 647-655, 658-662.
379. 2008 Papakostas G, Stahl S, Krishen A, Seifert C, Tucker V, Goodale E and Fava M. Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the treatment of Major Depressive Disorder with High Levels of Anxiety (Anxious Depression). J Clin Psychiatry 69: 8, 1287-1292.
380. 2008 Stahl SM. L-methylfolate: a vitamin for your monoamines; Journal of Clinical Psychiatry 69: 9; 1352-1353.
381. 2008 Stahl SM and Felker A. Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants. CNS Spectrums 13: 10, 855-870.
382. 2008 Stahl SM. The Sigma Enigma: Can Sigma Receptors Provide a Novel Target for Disorders of Mood and Cognition? Journal of Clinical Psychiatry 69: 11; 1673-1674.
383. 2008 Stahl SM. Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines. CNS Spectrums 13 (12): 1027-1038.
384. 2009 Kim D, Maneen M and Stahl SM. Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia. Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics. Vol.6, 78-85.
385. 2009 Stahl SM, Mignon L and Meyer JM. What Comes First: Atypical Antipsychotics or The Metabolic Syndrome? Acta Psychiatrica Scand 119: 171-179.
386. 2009 Meyer JM and Stahl SM. The Metabolic Syndrome and Schizophrenia. Acta Psychiatrica Scand 119: 4-14.
387. 2009 Stahl SM. Vasomotor Symptoms and Depression in Women, Part 1. Journal of Clinical Psychiatry 70: 1, 11-13.

PUBLICATIONS (34)

388. 2009 Stahl SM. Multifunctional Drugs: A Novel Concept for Psychopharmacology. CNS Spectrums 14: 2, 71-73.
389. 2009 Stahl SM. Vasomotor Symptoms and Depression in Women, Part 2: Treatments that cause remission and prevent Relapses of Major Depressive Episodes Overlap with Treatments for Vasomotor Symptoms. Journal of Clinical Psychiatry 70: 3, 310-311.
390. 2009 Hayashi T and Stahl SM. Sigma 1 receptors and its role in the treatment of mood disorders. Drugs of the Future 34 (2): 137-146.
391. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Overview and Finding the Focus. CNS Spectrums 14: 4, 179-182.
392. 2009 Stahl SM. Norepinephrine and Dopamine Regulate Signals and Noise in the Prefrontal Cortex. J Clin Psychiatry 70:5, 617-618.
393. 2009 Mischoulon D, Fava M and Stahl SM. Letter to the Editor. Folate Supplementation: Is It Safe and Effective? J Clin Psychiatry 70: 5, 767-769.
394. 2009 Munk-Jorgensen P, Nielsen J, Nielsen RE and Stahl SM. Last Episode Psychosis. Acta Psychiatrica Scandinavica. 119:417-418.
395. 2009 Stahl SM and Briley M. Why Psychiatrists should not ignore pain in their patients -focus on fibromyalgia? Human Psychopharmacology 24: S1-S2.
396. 2009 Stahl SM. Fibromyalgia – pathways and neurotransmitters. Human Psychopharmacology 24: S11-S17.
397. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Storyboarding a Presentation and the Rule of Small Multiples. CNS Spectrums 14: 6, 288-294.
398. 2009 Stahl SM. The Prefrontal Cortex Is Out of Tune in Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry 70: 7, 950-951.
399. 2009 Stahl SM, Lombardo I, Loebel A and Mandel F. Efficacy of Ziprasidone in Dysphoric Mania: Pooled Analysis of 2 Double Blind Studies. Journal of Affective Disorders 122' 30-45.
400. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Audience Response Systems. CNS Spectrums 14: 8, 412-414.
401. 2009 Stahl SM. Epigenetics and Methylomics in Psychiatry. J Clin Psychiatry 70: 9, 1204-1205.

PUBLICATIONS (35)

402. 2009 Stahl SM. Mechanism of Action of Trazodone: a Multifunctional Drug. CNS Spectrums 14: 10, 536-546.
403. 2009 Stahl SM. Combining Antidepressant Therapies From the Initiation of Treatment: A Paradigm Shift for Major Depression. J Clin Psychiatry Nov; 70(11):1493-4.
404. 2009 Stahl SM. Crisis in Army Psychopharmacology and Mental Health Care at Fort Hood. CNS Spectrums 14:12, 677-684.
405. 2010 Stahl SM. Mechanism of Action of Stimulants in Attention Deficit/Hyperactivity Disorder. J Clin Psychiatry Jan; 71 (1): 12-13.
406. 2010 Sussman N and Stahl SM. The Future of Novel Drug Discovery in CNS. IN SESSION with Stephen M. Stahl, M.D.,Ph.D. Primary Psychiatry 17 (1): 32-34.
407. 2010 Stahl SM. Enhancing Outcomes from Major depression: Using Antidepressant Combination Therapies with Multifunctional Pharmacological Mechanisms from the Initiation of Treatment, CNS Spectrums 15: 2; p 677-691.
408. 2010 Stahl SM. Mechanism of Action of α 2A-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder With or Without Oppositional Symptoms, Journal of Clinical Psychiatry 71:3, p 223-224.
409. 2010 Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A and Post A. Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Journal of Clinical Psychopharmacology Volume 30, Number 2, 135-144.
410. 2010 Stahl SM. Methylated Spirits: Epigenetic Hypotheses of Psychiatric Disorders. CNS Spectrums 15: 4, 220-230.
411. 2010 Stahl SM. Circuits of Sexual Desire in Hypoactive Sexual Desire Disorder. Journal of Clinical Psychiatry 71:5, 518-519.
412. 2010 Stahl SM, Fava M, Trivedi M, Caputo A, Shah A and Post A. Agomelatine in the Treatment of Major Depressive Disorder: An 8 week, Multicenter, Randomized, Placebo-controlled Trial. Journal of Clinical Psychiatry 71: 5; 616-626.
413. 2010 Stahl SM. Fooling Mother Nature: Epigenetics and Novel Treatments for Psychiatric Disorders. CNS Spectrums 15: 6, 358-365.
414. 2010 Stahl SM. Psychiatric Stress Testing: Novel Strategy for Translational Psychopharmacology. Neuropsychopharmacology 35: 6, 1413-1414.

PUBLICATIONS (36)

415. 2010 Stahl SM. Targeting Circuits of sexual Desire as a Treatment Strategy for Hypoactive sexual Desire Disorder. Journal of Clinical Psychiatry 71: 7, 821-822.
416. 2010 Stahl SM, Davis RL, Kim DH, Lowe Gellings N, Carlson RE Jr, Fountain K and Grady MM. Play it Again: The Master Psychopharmacology Program as an Example of Interval Learning in Bite-Sized Portions. CNS Spectrums 15: 8, 491-504.
417. 2010 Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PF, Harvey PD, Loebel A, Watsky E, Siu CO and Romano S. A Post Hoc Analysis of Negative Symptoms And Psychosocial Function in Patients with Schizophrenia: A 40-Week, Randomized, Double-Blind Study of Ziprasidone versus Haloperidol Followed by a 3 Year Double-Blind Extension Trial. Journal of Clinical Psychopharmacology Volume 30, Number 4, 425-430.
418. 2010 Mignon L and Stahl SM. Current Depression Landscape: A State of the Field Today. In: Next General Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders. Eds: Beyer CE and Stahl SM. Cambridge University Press, New York, NY, 1 - 11.
419. 2010 Grady M and Stahl SM. Antidepressants: Recent Developments. In Encyclopedia of Psychopharmacology. Springer Publishing, New York, 101-108.
420. 2010 Stahl SM. Illustrating the Circuits of Sexual Desire. Journal of Clinical Psychiatry 71: 9, 1113-1114.
421. 2010 Nutt D and Stahl SM. Searching for perfect sleep: the continuing evolution of GABA_A receptor modulators as hypnotics. J Psychopharmacology 24 (11); 1601-1602.
422. 2010 Stahl SM. The Serotonin-7 Receptor as a Novel Therapeutic Target. Journal of Clinical Psychiatry 71: 11, 1414-1415.
423. 2010 Loonen AJM and Stahl SM. The Mechanism of Drug-induced Akathisia. CNS Spectrums 15; 11, 491-494.
424. 2010 Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatrica Scand 122: 440-441.
425. 2010 Loonen AJM and Stahl SM. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatrica Scand 122: 435-437.

PUBLICATIONS (37)

426. 2010 Kim D and Stahl SM. Antipsychotic Drug Development. In: Current Topics in Behavioral Neurosciences 4: Behavioral Neurobiology of Schizophrenia and Its Treatment. Eds: Geyer MA, Ellenbroek BA and Marsden CA. Springer Publishing, p. 123-139.
427. 2011 Munk-Jorgensen P, Christiansen B, Stahl SM and Licht, RW. Happy new year 2011. Acta Psychiatr Scand 123: 1; 1-3.
428. 2011 Stahl SM, Sommers B and Allers K. Multifunctional pharmacology of flibanserin: Possible mechanism of action in hypoactive sexual desire disorder. J Sex Med 8: 15-27.
429. 2011 Mattei C, Rapagnani MP and Stahl SM. Ziprasidone Hydrochloride: what role in the management of schizophrenia? Journal of Central Nervous System Disease 3: 1-16.
430. 2011 Schwartz TL and Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neuroscience and Therapeutics 17; 110-117.
431. 2011 Schwartz TL, Stahl SM, Pappadopulos E and Karayal ON. Ziprasidone in the treatment of bipolar disorder. In: Bipolar Psychopharmacotherapy: Caring for the Patient, 2nd edition. Eds: Akiskal H and Tohen M, Wiley Press, p 223-244.
432. 2011 Schwartz TL and Stahl SM. Optimizing Antidepressant Management of Depression: Current Status and Future Perspectives. In: Depression: From Psychopathology to Pharmacotherapy. The Future of Antidepressants. Eds: Cryan FJ and Leonard BD. S. Karger AG, Basel, Switzerland 2010, p 254-267.
433. 2011 Loonen AJM, Stahl SM and van Praag HM. Letter to the Editor. Reply to: Case Studies are not sufficient. Acta Psychiatr Scand 123: 493-494.
434. 2011 Sauve W and Stahl SM. Psychopharmacological Treatment of PTSD. In: Handbook for the Treatment of PTSD in Military Personnel. Eds: Moore BA and Penk WE, Guilford Press, p 155-172.
435. 2011 Schwartz TL, Siddiqui UA and Stahl SM. Vilazodone: A Brief Pharmacologic And Clinical Review of the Novel SPARI (Serotonin Partial Agonist and Reuptake Inhibitor). Therapeutic Advances in Psychopharmacology Volume 1 Issue 3, 81-87.
436. 2011 Morrisette DA and Stahl SM. Affective Symptoms in Schizophrenia. In: Drug Discovery Today: Therapeutic Strategies, Volume 8, Issues 1-2, p 3-9.

PUBLICATIONS (38)

437. 2012 Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short- term treatment of schizophrenia: a post hoc analysis of pooled patient data from 4 Phase II, Placebo- and active-controlled trials, Human Psychopharmacology. 27: 24-32.
438. 2012 Stahl SM, Psychotherapy as an epigenetic “drug”: psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs. Journal of Clinical Pharmacy and Therapeutics. 37: 249-253.
439. 2012 Brandt MR, Beyer CE and Stahl SM. TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. Pharmaceuticals, special issue "Emerging Pain Targets and Therapy", 5, 114-132.
440. 2012 Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH, Sahakian BJ. A Plan for mental illness. Nature, Vol 483, 269.
441. 2012 Schwartz TL, Sachdeva S and Stahl SM. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia, Current Pharmaceutical Design 18, 1580-1592
442. 2012 Grady M and Stahl SM. Practical Guide for Prescribing MAOI: Debunking Myths and Removing Barriers. CNS Spectrums 17, 2-10.
443. 2012 Stahl SM. CNS Spectrums: a new publisher, a new editor-in-chief, and new vistas. CNS Spectrums 17, 1.
444. 2012 Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatrica Scandinavica 125: 349-351.
445. 2012 Grady M and Stahl SM. A horse of a different color: how formulation Influences medication effects. CNS Spectrums 17. 63-69.
446. 2012 Gellings-Lowe N and Stahl SM. Antidepressants in pain, anxiety and depression. In: Pain Comorbidities. Giamberardino MA and Jensen TS (Eds), IASP Press, 409-423.
447. 2012 Tarazi F and Stahl SM. Iloperidone, asenapine and lurasidone: a primer on Their current status. Expert Opinion on Pharmacotherapy 13 (13); 1911-1922.
448. 2012 Gellings Lowe N, Rapagnani MP, Mattei C and Stahl SM. The Psychopharmacology of Hallucinations: Ironic Insights Into Mechanisms of Action. In: The Neuroscience of Hallucinations. Eds: Jardri R, Thomas P, Cachia A and Pins D. Springer Press, 471-492.

PUBLICATIONS (39)

449. 2012 Griebel G, Beeske S and Stahl SM. The V1b receptor antagonist SSRI49415 in the treatment of major depressive and generalized anxiety disorders: results from four double-blind, placebo-controlled studies. J Clin Psychiatry 73: 11, 1403-1411.
450. 2012 Schwartz TL, Sachdeva S and Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Frontiers in Pharmacology Volume 3, 1-11.
451. 2012 Stahl SM. Structural Imaging of schizophrenia: is the modern psychiatrist becoming a "disease scene investigator?". Acta Psychiatrica Scandinavica 126: 231-232.
452. 2012 Morrisette DA and Stahl SM. Optimizing Outcomes in Schizophrenia: Long Acting Depots and Long Term Treatment. CNS Spectrums 17: 10-21.
453. 2012 Lum CT and Stahl SM. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectrums 17: 107-120.
454. 2012 Sfera A and Stahl S. A Century of Schizophrenia Where We Came From, Where We Are now and Where We are Going. Romanian Journal of Psychopharmacology 12: 201-217.
455. 2012 Chang TE and Stahl SM. Developments in Psychopharmacology for Major Depressive Disorder. FOCUS 10: 452-460.
456. 2013 Stahl SM. The Tyranny of the majority and the interchangeability of drugs. Acta Psychiatrica Scandinavica 127: 4-5.
457. 2013 Stahl SM. Kick-off Editorial for 2013: Thanks to our Reviewers. CNS Spectrums, 18: 1; 5.
458. 2013 Stahl SM. Off label prescribing: Best Practice or Malpractice. CNS Spectrums, 18: 1, 1-4.
459. 2013 Stahl SM. The Last Diagnostic and Statistical Manual (DSM): replacing Our symptom-based diagnoses with a brain circuit-based classification of mental Illnesses. CNS Spectrums 18, 65-68.
460. 2013 Stahl SM, Cucchiario J, Sinonelli, D, Severs J, Pikalov A and Loebel A. Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-month, Open-Label Study. J Clin Psychiatry 74: 5, 507-515.

PUBLICATIONS (40)

461. 2013 Stahl SM, Lee-Zimmerman C, Cartwright S and Morrissette DA. Serotonergic Drugs for Depression and Beyond. Current Drug Targets 14: (5); 578-585.
462. 2013 Stahl SM. Classifying psychotropic drugs by mode of action and not by Target disorder. CNS Spectrums 18, 113-117.
463. 2013 Stahl SM, Eisenach JC, Taylor CP, Cheung RY, Thorpe A and Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacologic activities. Trends in Pharmacological Science. 34: 6; 332-339.
464. 2013 Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O'Day JA, Dardashti LJ and Warburton KD. "Meta-guidelines" for the Management of patients with schizophrenia. CNS Spectrums 18, 150-162.
465. 2013 Morrissette DA and Stahl SM, Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In Ritsner MS, Polypharmacy in Psychiatric Practice, Volume.I, 107-125.
466. 2013 Schwartz TL, Siddiqui U and Stahl SM. Translating Basic Science into Clinical Practice while Dosing the Second Generation antipsychotics. In: Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, p 55-78.
467. 2013 Stahl SM. Translating from neuroscience to psychiatry (and back translating from psychiatry to neuroscience) Acta Psychiatrica Scandinavica 128: 103-104.
468. 2013 Stahl SM. Controversies in treating bipolar Depression. CNS Spectrums 18, 175-176
469. 2013 Stahl SM. Mechanism of action of ketamine. CNS Spectrums 18, 171-174.
470. 2013 Stahl SM. Mechanism of Action of dextromethorphan/quinidine: comparison with ketamine. CNS Spectrums 18, 225-227.
471. 2013 Grady MM and Stahl SM. Novel Agents in Development for the treatment of depression. CNS Spectrums 18, Supplement 1, 37-41.
472. 2013 Stahl SM. Role of $\alpha 1$ adrenergic antagonism in the mechanism of action Of iloperidone: reducing extrapyramidal symptoms. CNS Spectrums 18, 285-288.
473. 2013 Stahl SM. Emerging Guidelines for the Use of Antipsychotic Polypharmacy. Revista de Psiquiatria Y Salud Mental 6 (3): 97-100.

PUBLICATIONS (41)

474. 2013 Inset TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kipfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH and Sahakian BJ. Innovative Solutions to Novel Drug Development in Mental Health. Neuroscience and Biobehavioral Reviews 37: 2438-2444.
475. 2014 Opler LA, Medalia A, Opler MG and Stahl SM. Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectrums 19: 142-156
476. 2014 Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M and Stahl SM. A Proposal For An Updated Neuropsychopharmacological Nomenclature. European Neuropsychopharmacology, 24: 1005-1014
x.doi.org/10.11016/j.euroneuro.2013.08.004
477. 2014 Stahl SM. Long-Acting injectable antipsychotics: shall the last be first? CNS Spectrums 19, 3-5.
478. 2014 Stahl SM. Kick-off editorial for 2014: Thanks to our reviewers. CNS Spectrums 19, 1-2.
479. 2014 O'Day J. A., Dardashti L. J., Delgado D. M., Schwartz E. H., Broderick C. L. and Stahl S. M. Genetics and Epigenetics of Mental Illness: Implications for Diagnosis and Treatment. Wiley Encyclopedia of Forensic Science. 1–9. Eds A. Jamieson and A.A. Moenssens, John Wiley, Chichester
480. 2014 Stahl SM. Mechanism of action of the SPARI vilazodone: (serotonin partial agonist Reuptake inhibitor) CNS Spectrums 19, 105-109.
481. 2014 Stahl SM. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectrums 19, 207-212.
482. 2014 Stahl SM. Clozapine: Is Now the Time for More Clinicians to Adopt this Orphan? CNS Spectrums 19, 279-281.
483. 2014 Grady MM and Stahl SM. Antidepressants: Recent Developments (Category: Drugs and Drug Classes). Encyclopedia of Psychopharmacology DOI 10.1007/978-3-642-27772-6_362-2, p 1-9.
484. 2014 Stahl SM. Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectrums 19, 357-365.
485. 2014 Morrissette DA and Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectrums 19, 439-448.

PUBLICATIONS (42)

486. 2014 Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S and Warburton K. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectrums 19, 449-465.
487. 2014 Stahl SM. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. CNS Spectrums 19, 475-487.
488. 2014 Shapiro DN and Stahl SM. Novel and Investigational Drugs in Depression. International Neuropsychiatric Disease Journal 2 (6): 328-347.
489. 2014 Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM and Fava M. Effect of Adjunctive L-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial. J Clin Psychiatry 75: 8, 855-863.
490. 2014 Morrissette DA and Stahl SM. Modulating the Serotonin System in the treatment of major depressive disorder. CNS Spectrums 19, Supplement 1, 57-69.
491. 2015 Burton B, Feigenbaum A, Grant M, Hendren R, Singh R, Siriwardena K, Phillips III J, Sanchez-Valle A, Waisbren S, Gillis J, Prasad S, Merilainen M, Lang W and Stahl SM. A Randomized, Double-Blind study Exploring ADHD Symptoms and Executive Function in People with Phenylketonuria Randomized to Sapropterin Dihydrochloride or Placebo. Molecular Genetics and Metabolism 114: 415-424; doi: 10.1016/j.ymgme.2014.11.011.
492. 2015 Stahl SM, Kick Off Editorial for 2015: thanks to our reviewers; CNS Spectrums 20: 7-8
493. 2015 Stahl SM. Mechanism of action of Flibanserin, a Multifunctional Serotonin Agonist and Antagonist (MSAA), in Hypoactive Sexual Desire Disorder. CNS Spectrums 20: 1-6
494. 2015 Stahl SM, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors); CNS Spectrums 20: 93 – 97
495. 2015 Stahl SM, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine; CNS Spectrums 20: 455-459

PUBLICATIONS (43)

496. 2015 Stahl SM, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release, CNS Spectrums 20: 331 - 336
497. 2015 Stahl SM Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters, CNS Spectrums 20: 515 – 519
498. 2015 Stahl SM Is impulsive violence an addiction? The Habit Hypothesis, CNS Spectrums 20: 165 – 169
499. 2015 Culpepper, L, Muskin PR, Stahl SM, Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability, American Journal of Medicine 128, S1-S15
500. 2015 Warburton KD, Stahl SM, Treat the treatable: a comprehensive and optimistic approach to treating psychiatric violence, CNS Spectrums 20: 170 – 171 (editorial)
501. 2015 Schaufenbil RJ, Kornbluh R, Stahl SM, Warburton KD, Forensic focused treatment planning: a new standard for forensic mental health systems CNS Spectrums 20: 250 – 253
502. 2015 Zohar J, Stahl SM, Moller H-J, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin GM, Nutt D, A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature, European Neuropsychopharmacology, 25: 2318-25
503. 2015 Stahl SM, Using neuroscience for naming psychotropic drugs, CNS Spectrums 21: 219-220 (editorial)
504. 2015 Maxwell NM, Nevin RL, Stahl SM, Block J, Shugarts S, Wu AH, Dominy S, Solano-Blanco MA, Kappelman-Culver S, Lee-Messer C, Maldonado J, Maxwell AJ, Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy doi: 10.1002/ccr3.238; Clinical Case Reports 3:379-87.
505. 2015 Shapiro DN and Stahl SM, Psychopharmacology Child and Adolescent, Wiley Encyclopedia of Forensic Science. 1–9. eds A. Jamieson and A.A.Moenssens, John Wiley: Chichester. doi: 10.1002/9780470061589.fsa1105. Published 16th June 2014.
506. 2016 Stahl SM, Kick-off editorial for 2016: thanks to our reviewers, CNS Spectrums 21:7-8

PUBLICATIONS (44)

507. 2016 Stahl SM, Mechanism of action of brexpiprazole: comparison with aripiprazole, CNS Spectrums 21:1 - 6
508. 2016 Stahl SM Mechanism of action of cariprazine, CNS Spectrums 21: 23-127
509. 2016 Stahl SM Mechanism of action of suvorexant, CNS Spectrums 21:215 – 218
510. 2016 Stahl SM Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT_{2A} and 5HT_{2C} receptors, CNS Spectrums 21: 271 – 275
511. 2016 Stahl SM, Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome, CNS Spectrums 21: 355-359.
512. 2016 Stahl SM, Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? CNS Spectrums 21: 419-423.
513. 2016 Meyer JM, Cummings MA, Proctor G, Stahl SM, Psychopharmacology of Persistent Violence and Aggression, Psychiatr Clin N Am 39 (2016) 541–556.
514. 2016 Meyer JM, Proctor G, Cummings MA, Dardashti LJ, Stahl, SM, Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction, Case Reports in Psychiatry Volume 2016, Article ID 5606098, 7 pages (<http://dx.doi.org/10.1155/2016/5606098>).
515. 2016 Moore BA, Morrisette DA, Meyer JM, Stahl SM, "Unconventional" Treatment Strategies for Schizophrenia: Polypharmacy and Heroic Dosing BJPsychBull 1-5, 41:164-168, doi: 10.1192/pb.bp.115.053223.
516. 2017 Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Phaus J, Simon JA, Kingsberg SA, Meston C. Stahl SM, Wallen K, Worsley R, HSDD Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review, Mayo Clinic. (<http://creativecommons.org/licenses/by-nc-nd/4/>; Mayo Clin.Proc. 92:114-128.
517. 2017 Nutt D, Stahl S, Drago F, Zohar J, Wilson S, Inverse agonists – What do they mean for psychiatry? European Neuropsychopharmacology, 27: 87-90, (<http://dx.doi.org/10.1016/j.euroneuro.2016.11.013>).
518. 2017 Sabbag SA, Alhajji L, Saveanu RV, Stahl SM, Nemeroff CB, Teaching Neurobiology in Psychiatry, chapter in Hermans, MHM, Hoon, TC, Pi,(Eds), EH Mental Health and Illness Worldwide: Education about Mental Health and Illness. Springer, New York, Chapter 11, 2018

PUBLICATIONS (45)

519. 2017 Stahl SM Neuroscience-based Nomenclature: Classifying Psychotropics by Mechanism of Action Rather Than Indication, Current Psychiatry 2017; 16: 15-16
520. 2017 Keppel Hesselink, JM, Kopsky DJ, Stahl SM, Bottlenecks in the Development of Topical Analgesics: Molecule, Formulation, Dose-Finding and Phase III Design, J Pain Res 2017; 10:635-41
521. 2017 Stahl SM Kick off editorial for 2017: CNS Spectrums is on the move, CNS Spectrums 2017, 22:5-6
522. 2017 Stahl SM Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice, CNS Spectrums 2017; 22:1-4
523. 2017 Stahl SM, Mixed-up About How to Diagnose and Treat Mixed Features in Major Depressive Episodes, CNS Spectrums (2017), 22, 111–115
524. 2017 Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, Lee Y, Malhi G, Marangoni C, McElroy SL, Ostracher M, Rosenblat JD, Sole E, Suppes T, Takeshima M, Thase ME, Vieta E, Young A, Zimmerman M, McIntyre RS, Guidelines for the Recognition and Management of Mixed Depression, CNS Spectrums, 22: 203–219
525. 2017 Stahl SM, Does Treating Hearing loss prevent or slow the progress of dementia: Hearing is not all in the ears, but who’s listening, CNS Spectrums, 22: 247-250, DOI: <https://doi.org/10.1017/S1092852917000268>.
526. 2017 Shapiro D, Stevens D, Stahl SM, Flibanserin – the female Viagra? International Journal of Psychiatry in Clinical Practice, 21:4, 259-265 DOI:10.1080/13651501.2017.1315138,
527. 2017 Stevens DM, Weems JM, Brown L, Barbour KA, Stahl SM, The Pharmacodynamic Effects of Combined Administration of Flibanserin and Alcohol, AJ Clin Pharmacy and Therapeutics, 42: 598-606, DOI: 10.1111/jcpt.12563
528. 2017 Stahl SM, Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors, CNS Spectrums, 22: 305-311
529. 2017 Stahl SM, Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes, CNS Spectrums, 22: 375-384
530. 2017 Stahl SM, Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum, CNS Spectrums, 22, 427-434
531. 2017 Stahl SM, Morrissette DA, Does a “whiff” of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic? Wiley Bipolar Disorders, 19: 595-596, DOI: 10.1111/bdi.12542

PUBLICATIONS (46)

532. 2018 Cummings MA, Proctor GJ, Stahl SM, Deuterium Tetrabenazine for Tardive Dyskinesia, Clinical Schizophrenia & Related Psychoses, Winter 2018, 214-220.
533. 2018 Lemoine P, Stahl SM, Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties, CNS Spectrums, 22:15-25
534. 2018 Hesselink Keppel JM, Stahl SM, Phenytoin in Bipolar Depression: An Old Chapter, but Not Yet Properly Evaluated, Journal of Mood Disorders and Therapy, 1: 24-28
535. 2018 Stahl SM, Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects, CNS Spectrums, 23: 1-6
536. 2018 Stahl SM, Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough, CNS Spectrums, 23: 113-116
537. 2018 Stahl SM, Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate, CNS Spectrums, 23: 187-191
538. 2018 Stahl SM, Comparing pharmacological mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectrums 23:
539. 2018 Stahl SM, New Hope for Alzheimer’s Dementia as Prospect for Disease Modification Fade: Symptomatic Treatments for Agitation and Psychosis, CNS Spectrums 23: 291-297
540. 2018 Muse MD and Stahl SM, Anxiety Disorders: Evidence-Based Integrated Biopsychological Treatment in Cognitive Behavior, Psychopharmacology: The Clinical Evidence Based Biopsychological Integration, Wiley Blackwell, Chichester, UK, 2018
541. 2018 Marazziti D, Stahl SM, Evil, terrorism, and psychiatry, CNS Spectrums, 23: 117-118
542. 2018 Marazziti D, Stahl SM, Serotonin and Love Supporting Evidence From a Patient Suffering From Obsessive-Compulsive Disorder, Journal of Clinical Psychopharmacology, 38: 1-2

PUBLICATIONS (47)

543. 2019 Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrisette DA, Stahl SM, Guidance for Switching from Off-Label Antipsychotics to Pimavanserin for Parkinson's Disease Psychosis: An Expert Consensus, CNS Spectrums, 23: 402-413
544. 2019 McIntyre RS, Anderson N, Baune BT, Brietzke E, Burdick K, DiSimplicio M, Fossati P, Harmer C, Gorwood P, Harrison J, Harvey P, Holmes E, Ji J, Mansur RB, Medalia A, Miskowiak K, Ramey T, Rong C, Rosenblat JD, Young A, Stahl SM, Expert consensus on screening assessment of cognition in psychiatry, CNS Spectrums, 24: 154-162
- 545: 2019 Sauve W, Stahl SM, Psychopharmacological and Neuromodulation Treatment of PTSD, 2nd Edition, Handbook for the Treatment of PTSD in Military Personnel, Moore BA and Penk WE, Guilford Press: 155-172.
546. 2019 Fountoulakis KN, Stahl SM, Biological Psychiatry and Psychopharmacology, in Fountoulakis KN, Nimatoudis I (Eds), Psychobiology of Behavior, Springer Nature Switzerland AG 2019, 13:397-458; doi.org/10.1007/978-3-030-18323-3
547. 2019 Marazziti D, Stahl SM, Simoncini, M, Baroni S, Mucci F, Palego L, Betti L, Massimetti G, Giannaccini G, Dell'Osso L, Psychopharmacology and Ethnicity: A Comparative Study on Senegalese and Italian Men, World Journal of Biologic, Psychiatry 2020;21(4):300-7; doi.org/10.1080/15622975.2019.1583373.
548. 2019 Stahl SM, Placebo Response Rate is Ruining Drug Development in Psychiatry: Why Is This Happening and What Can We Do About It? Acta Psychiatrica Scandinavia, 2019; 139: 105-107
549. 2019 Stahl SM, Morrisette DA, Mixed Mood States: Baffled, Bewildered, Befuddled and Bemused, Bipolar Disorders 2019;21(6):560-1. doi.org/10.1111/bdi.12787
550. 2019 Stahl SM, Mechanism of Action Dextromethorphan / Bupropion: A Novel on NMDA Antagonist with Multimodal Activity, CNS Spectrums, 2019; 24: 461-466
551. 2019 McIntyre RS, Suppes T, Early W, Patel M, Stahl SM. Cariprazine Efficacy in Bipolar I Depression With and Without Concurrent Manic Symptoms: Post Hoc Analysis of Three Randomized, Placebo-Controlled Studies, CNS Spectrums, 2019; 25(4), 502–510. <https://doi.org/10.1017/S1092852919001287>
552. 2019 O'Connor PJ, Kennedy DO, Stahl SM. Mental Energy: Plausible Neurobiology Mechanisms and Emerging Research on the Effects of Natural Dietary Components, Nutritional Neuroscience, doi.org/10.1080/1028415X.2019.1684688

PUBLICATIONS (48)

553. 2020 Stahl SM, Laredo SA, Morrissette DA, Cariprazine as a Treatment Across the Bipolar I Spectrum from Depression to Mania: Mechanism of Action and Review of Clinical Data, Therapeutic Advances in Psychopharmacology, 2020;10:2045125320905752
554. 2020 Pompili M, Vazquez GH, Forte A, Morrissette DA, Stahl SM. Pharmacological Treatment of Mixed States, Psychiatric Clinics of North America, 2020;43(1):167-86.
555. 2020 Marazziti D, Stahl SM. Novel challenges to psychiatry from a changing world, CNS Spectrums <https://doi.org/10.1017/S1092852919001858>
556. 2020 Delgado D, Breth A, Hills, Warburton K, Stahl SM. Economics of Decriminalizing Mental Health Illness: When Doing the Right Thing Ironically Costs Less, CNS Spectrums, 2020; 25:566-570
<https://doi.org/10.1017/S1092852919001792>
557. 2020 Warburton K, McDermott BE, Gale A, Stahl SM. Survey of National Trend in Psychiatric Patients Found Incompetent to Stand Trial: Reason for Re-Institutionalization of People With Serious Mental Illness in the United States, CNS Spectrums, 2020; 25:245-51. <https://doi.org/10.1017/S1092852919001585558>.
558. 2020 Rose B, Broderick C, Delgado D, Kornbluh R, Stahl SM. Breaking down long term chronic aggression, CNS Spectrums, 2020; 25:216-222.
<https://doi.org/10.1017/S1092852919001317>
559. 2020 Daugherty B, Warburton K, Stahl, SM. A Social History of Mental Illness, CNS Spectrums, 2020: 25:584-92. <https://doi.org/10.1017/S1092852920001364>
560. 2020 Warburton K, Stahl SM. Editorial Balancing the Role of Institutionalization in the Treatment of Serious Mental Illness, CNS Spectrums, 2020; 25:115-118.
<https://doi.org/10.1017/S1092852920000176>
561. 2020 Poole J, Reddy H, Maguire G, Stahl SM. New Pharmacological Approaches, Psychiatric Clinics of North America, 2020; 43:399-413.
<https://doi.org/10.1016/j.psc.2020.02.008>
562. 2020 Marazziti D, Stahl SM. The relevance of COVID-19 pandemic to psychiatry, World Psychiatry 2020; 19:261
563. 2020 Cummings MA, Scott C, Arguello JC, Arias A-LW, Breth AM, Delgado D, Harvey PD, Meyer JM, O'Day J, Pollock M, Proctor G, Rector T, Rose B, Schwartz E, Thordason H, Warburton KD, and Stahl SM. The Cal-DSH Diversion Guidelines, CNS Spectrums 2020; 25: 701-13. <https://doi.org/10.1017/S1092852920001819>

PUBLICATIONS (49)

564. 2020 Cummings JL, Devanan DP, Stahl SM. Dementia-Related Psychosis and the Potential Role for Pimavanserin, CNS Spectrums, DOI: 10.1017/S1092852920001765
565. 2021 Stahl SM, Sy S, Maguire GA. How and When to Treat the Most Common Adverse- Effects of Antipsychotics: Expert Review from Research to Clinical Practice, Acta Psychiatrica Scandinavica DOI: 10.1111/acps.13266
566. 2021 McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Jaramillo CL, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA, Stahl SM. Synthesizing the Evidence for Ketamine and Esketamine in Treatment Resistant Depression: Guidance and International Perspective, Am J Psychiatry (doi:10.1176/appi.ajp2020.20081251
567. 2021 De Martin S, Gabbia D, Folli F, Bifari F, Fiorina P, Ferri N, Stahl S, Inturrisi CE, Pappagallo M, Traversa S, Manfredi PL. REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study, Frontiers in Pharmacology, doi 10.3389/fphar.2021.6718
568. 2021 Fava M, Stahl S, Pani L, DeMartin S, Alimonti A, Bettini E, Wessel T, de Somer M, Caron J, Pappagallo M, Vitolo OV, DiGuglielmo G, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Traversa S, Inturrisi CE, Manfredi PL. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients with Major Depressive Disorder: a Phase 2a Double-Blind Randomized Trial, American Journal of Psychiatry doi.org/10.1176.appi.ajp.2021.21020197
569. 2021 Albert U, Lamba P and Stahl SM. Early Response to Trazodone in Major Depressive Disorder: Review of the Clinical Data and Putative Mechanism for Faster Onset of Action, CNS Spectrums doi.org/10.1017/S10928529210000304
570. 2021 Fountoulakis KN and Stahl SM. Precision and Personalized Assessment, Diagnosis and Treatment in Psychiatry, CNS Spectrums, doi.org/10.1017/S1092852920000139.
571. 2021 Ingram M, Maguire G, Stahl SM. Multifunctional Antidepressant Medications, Advances in Psychiatry and Behavioral Health, 1:185-203
572. 2021 Stahl SM, Segal S. The Third Generation of Therapeutic Innovation and the Future of Psychopharmacology, Current Psychiatry, 20: 6-25
573. 2021 Marazziti D, Stahl SM. Response to the Letter to the Editor “Psychiatry’s Undeclared Identity Crisis in a Changing World” by Richard Skaff, CNS Spectrums <https://doi.org/10.1017/S1092852921000559>

PUBLICATIONS (50)

574. 2022 Pandi-Perumal SR, Zaki NFW, Qasim M, Morsy NE, Manzar D, BaHammam AS, Jahrami H, Ramasubramanian C, Karthikeyan R, Supasitthumrong T, Moscovitch A, Trakht I, Gupta R, Narasimhan M, Partonen T, Reiter RJ, Morris G, Berk M, Kennedy SH, Stein DJ, Stahl SM, Charney DS, Seeman MV. Neuropsychiatric Consequences of COVID-19 Pandemic: A Synthetic Review From a Global Perspective, Alpha Psychiatry, DOI: 10.5152/alphapsychiatry.2022.21783
575. 2022 Fountoulakis KN, and Stahl SM. The Effect of Antipsychotic Treatment on Brain Morphology in Schizophrenia: A Systematic Review of Longitudinal Magnetic Resonance Studies with a Randomized Allocation to Treatment Arms, J Psychopharmacology DOI: 10.1177/02698811221087645 journals.sagepub.com/home/jop
576. 2022 Grover D, Tom M, Maguire G, Stahl SM, Polypharmacy – Purpose, Benefits and Limitations, Current Medicinal Chemistry , 1-9; <http://dx.doi.org/10.2174/0929867329666220107153813>
577. 2022 Thase ME, Stahl SM, McIntyre RS, Matthews-Hayes T, Rolin D, Patel M, Harrington A., Maletic V, Jackson WC, Vieta E. Screening for bipolar I disorder and the rapid mood screener: results of a nationwide healthcare provider survey CNS Spectrums 26(2), 181–183. <https://doi.org/10.1017/S1092852921000201>
578. 2022 Hong J, Vernon D, Kunovac J, Stahl SM. Emerging Drugs for the Treatment of Major Depressive Disorder, Expert Opinion on Emerging Drugs, DOI: 10.1080/14728214.2022.2117297
579. 2022 Bettini E, Stahl SM, DeMartin S, Mattarei A, Sgrignani J, Carignani C, Locatelli P, Pappagallo M, Inturrisi CE, Bifari F, Cavalli A, Alimont A, Pani L, Fava M, Traversa S, Folli F, Manfredi PL. Pharmacological Comparative Characterization of REL-1017 (esmethadone HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-methyl-D-aspartate Receptors, Pharmaceuticals **2022**, 15, 997. <https://doi.org/10.3390/ph15080997>
580. 2022 Bettini E, De Martin S, Mattarei A, Pappagallo M, Stahl SM, Bifari F, Inturrisi CE, Folli F, Traversa S, Manfredi PL, The N-Methyl-d-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid and Gentamicin, Pharmaceuticals 2022, 15, 882, <https://doi.org/10.3390/ph15070882>
581. 2022 Stahl SM, DeMartin S, Mattarei A, Bettini E, Pani L, Guidetti C, Folli F, deSomer M, Traversa S, Inturrisi CE, Pappagallo M, Gentilucci M, Alimont A, Fava M, Manfredi PL, Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling, Int. J. Mol. Sci. **2022**, 23, 12196. <https://doi.org/10.3390/ijms232012196>

PUBLICATIONS (51)

582. 2022 Dodd S, Norman TR, Carvalho AF, Eyre H, Stahl SM, Berk M. Psilocybin in Neuropsychiatry: A Review of its Pharmacology, Safety and Efficacy, 2022, CNS Spectrums <https://doi.org/10.1017/S1092852922000888>
583. 2022 Yohn, S, Weiden P Felder CC and Stahl SM, Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic, Trends in Pharmacological Sciences, 2022, Vol. 43, No. 12 <https://doi.org/10.1016/j.tips.2022.09.006>
584. 2022 Van den Eynde V, Wegdan R. Abdelmoemin WR, Abraham M, msterdam JD, Anderson IM, Andrade C, Baker GB, Beekman ATF, Berk M, Birkenhäger TK, Blackwell BB, Blier P, Blom MBJ, Bodkin AJ, Cattaneo CI, Dantz B, Davidson J, Dunlop BW, Estévez RF, Feinberg SS, Finberg JPM, Fochtmann LJ, Gotlib D, Holt A, Insel TR, Larsen JK, Mago R, Menkes DB, Meyer JM, Nutt DJ, Parker G, Rego MD, Richelson E, Ruhé HG, Sáiz-Ruiz J, Stahl SM, Steele T, Thase ME, Ulrich S, van Balkom AJLM, Vieta E, Whyte I, Young AH and Gillman PK The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression, CNS Spectrums 2022 <https://doi.org/10.1017/S1092852922000906>
585. 2022 Mattingly G, Matthews-Hayes T, Patel MD, Kramer K, Stahl SM. A survey of health care professionals and patients: do we need a new nomenclature for atypical antipsychotics? Prim Care Companion CNS Disord. 2023;25(0):22m03331.
586. 2022 Cooper T, Seigler M, Stahl SM, Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions, J Psychopharmacol DOI: 10.1177/02698811231158891 journals.sagepub.com/home/jop
587. 2022 Fava M, Stahl SM, DeMartin S, Mattarei A, Bettini E, Coai S, Alimonti A, Bifari F, Pani L, Folli F, Guidetti C, Traversa S, Inturrisi CE, Pappagallo M, Manfredi PL, Esmethadone-HCl (REL-1017): a promising rapid antidepressant, Eur Archives of Psychiatry and Clinical Neuroscience <https://doi.org/10.1007/s00406-023-1051-71-4>
588. 2023 Demyttenaere K and Stahl SM, Co-administration in the treatment of depression: deconstructing the Tower of Babel? European Neuropsychopharmacology, <https://doi.org/10.1016/j.euroneuro.2023>.
589. 2023 Thase ME, Stahl SM, McIntyre RS, Matthews-Hayes T, Rolin D, Patel M, Harrington A, Maletic V, Jackson WC, Vieta E, Screening for Bipolar I Disorder and the Rapid Mood Screener: Results of a Nationwide Health Care Provider Survey, Primary Care Companion CNS Disor 2023; 25(2):22m03322 <https://doi.org/10.4088/PCC.22m03322>

PUBLICATIONS (52)

590. 2023 Rossano F, Caiazza C, Sobrino A, Solini N, Vellucci A, Zotti N, Fornaro M, Gillman K, Cannaneo CI, Van den Eynde V, Stahl S, Iasevoli F, de Bartolmeis A, Efficacy and safety of selegiline across different psychiatry disorders: A systematic review and meta-analysis of oral and transdermal formulations, Euro Neuropsychopharmacol 2023, 72: 60-78 Selegiline efficacy and safety in Psychiatry: a systemic review and meta analysis. <https://doi.org/10.1016/j.euroneuro.2023.03.012>
591. 2023 Stahl SM, Djokic G, Comparing the pharmacology and pharmacokinetics of antipsychotics: choosing an antipsychotic and dosing a long-acting injectable, Euro Neuropsychopharm 2023, 73:108-118. <https://doi.org/10.1016/j.euroneuro.2023.04.015>
592. 2023 Grant ML, Jurecki ER, McCandless SE, Stahl SM, Bilder DA, Sanchez-Valle A, Dimmick D, Neuropsychiatric function improvement in pediatric patients with phenylketonuria, J Pediatrics 260:113626, <http://doi.org/10.1016/j.jpeds.2023.113526>
593. 2023 Goldberg JF, Steinman MQ, Stahl SM, Trazodone on once-a-day: a formula for addressing challenges in antidepressant safety and tolerability, Neurosci Applied 2: 101127, doi.org/10.1016/j.nsa.2023.101127
594. 2023 McIntyre RS, Maj M, Alsuwaidan M, Baune BT, Berk M, Cuijpers P, Demyttenaere K, Goldberg J, Gorwood P, Ho R, Kasper S, Kennedy S, Ly-Uson J, Mansur B, McCallister H, Murrugh J, Nemeroff C, Nierenberg A, Rosenblat JD, Rush J, Sanacora G, Schatzberg A, Shelton R, Stahl SM, Thase M, Trivedi M, Vieta E, Vinberg M, Williams N, Young A, Treatment resistant depression: scope, definitions, synthesis of the evidence and treatment guidelines, World Psychiatry, 2023; 22:394-412
595. 2023 Striebel JM, Oday J, Haghghat N, Stahl SM. Pimavanserin in Biological Therapies, Kaplan and Sadock, 11th edition, 2023
596. 2023 Osimo E, and Stahl SM, Neurotransmitters and receptors, in Lynell ML, Jones PB and Stahl SM, Cambridge Textbook of Neuroscience for Psychiatrists, Cambridge University Press, New York, 2023
597. 2023 Stead U, and Stahl, SM, Sleep, Regulation of Sleep and Arousal, Effects of Sleep Deprivation, in Lynell ML, Jones PB and Stahl SM, Cambridge Textbook of Neuroscience for Psychiatrists, Cambridge University Press, New York, 2023
598. 2023 Young A, Rucker J, Van den Eynde V, Redhead C, Barnett B, Godet L, Cleare A, Cosgrove J, Stahl S, Birkenhager T, Gillman PK, An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression, Part One, Psychiatric Annals 2023; 53:359-363

PUBLICATIONS (53)

599. 2023 Stahl S, Van den Eynde, V, Godet L, Redhead C, Gillman PK, The Pocket Guide to Classic Monoamine Oxidase Inhibitors for Treatment-Resistant Depression, Psychiatric Annals 223; 53: 347-352
600. 2023 Fond G, Mallet J, Urbach M, Benros Me, Berk M, Correll CU, Kulkarni J, Liora PM, Misdrahi D, Rey R, Schurhoff F, Somi M, Sommer, IEC, Stahl SM, Pignon B, Berna F, Adjunctive agents to antipsychotics in schizophrenia: umbrella review and GRADE recommendations for amino acids, hormonal therapies and anti-inflammatory drugs, BMJ Ment Health 2023 26: 1-7, <http://dx.doi.org/10.1136/bmjment-2023-300771>
601. 2024 Torres R, Czeisler EL, Chadwick SR, Stahl SM, Smieszek SP, Xiao C, Polymeropoulos CM, Birzioka G, Polyymeropoulos MH, Efficacy and safety of iloperidone in bipolar mania: a double blind, placebo controlled study, J Clin Psychiatry 2024;85(1):23m14966 doi.org/10.4088/JCP23m14966

602

IN PRESS PUBLICATIONS

1. Cummings MA, Arias AL, Proctor GJ, Stahl SM. Psychopharmacology of Chronic Aggression and Violence in Forensic Settings, in Kennedy HG and Davoren M, Seminars in Forensic Psychiatry, Gaskell, Royal College of Psychiatrists, Cambridge University Press.
2. Mattingly G, Hong J, Carbray JA, Cooper TV, Findling RL, Gignac M, Glaser PE, Lopez FA, Maletic V, McIntyre RS, Robb AS, Singh MK, Stein MA, Stahl SM, Expert consensus guidelines for telepsychiatry and Attention Deficit Hyperactivity Disorder, CNS Spectrums
3. McIntyre RS, Kwan ATH, Mansur RB, Nemeroff CB, Oliveira-Maia A, Rosenbatt JD, Stahl SM, Suppes T, Teopiz KM, Psychedelics for the Treatment of Psychiatric Disorders: A Synthesis and Guideline on Future Research, Clinical Development and Implementation, Am J Psychiatry

SUBMITTED PUBLICATIONS

1. McIntyre RS, Durgam S, Huo J, Koauer SG, Stahl SM, The efficacy of lumateperone in patients with bipolar depression with and without mixed features, J Clin Psychiatry